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ABSTRACT 
 
JIE TING: High-risk human papillomavirus testing of physician- and self-collected 
specimens for cervical cancer screening among female sex workers in Nairobi, Kenya 
(Under the direction of Jennifer S. Smith, PhD, MPH) 
A cervical cancer screening program based on high-risk human papillomavirus 
(hrHPV) testing of self-collected specimens (hrHPV self-testing) may help increase 
screening access in low-resource settings, thus reducing invasive cervical cancer (ICC) 
incidence in these regions. Little is known, however, about the performance of hrHPV testing 
with physician- collected versus self-collected specimens for cervical cancer screening 
among high-risk women in low-resource settings. In addition, to determine if a screening 
strategy is optimal for a given setting, the costs and benefits of each screening strategy must 
also first be compared. 
From 2009-2011, 344 female sex workers (FSW) in Nairobi participated in a study to 
compare hrHPV physician- versus self-testing for cervical cancer screening. Participants 
must have been between 18-50 years, had an intact uterus, and were not in the second 
trimester of pregnancy or later.  
HrHPV testing sensitivity for cytological high-grade squamous intraepithelial lesion 
or more severe (≥HSIL) was similar in physician- (86%) and self- collected specimens 
(79%). Specificity of hrHPV for ≥HSIL was also similar in physician- (73%) and self-
collected (75%) specimens. To determine the optimal screening strategy for our FSW 
population, we compared screening efficiency (number of colposcopies required to detect 
one histological cervical intraepithelial neoplasia 2 or more severe, ≥CIN 2) of three 
iv 
 
strategies (conventional cytology, hrHPV physician- and self-testing) for a once-in-a-lifetime 
cervical cancer screening. At a lower “willingness-to-pay” upper limit (number of 
colposcopies willing to conduct to detect a case of ≥CIN2) of <15 colposcopies per case of 
≥CIN 2 detected, conventional cytology was the optimal strategy for our FSW population, 
given the available information.  
 Screening using hrHPV self-testing in high-risk populations such as our FSW can be 
a reliable tool for cervical cancer screening, comparing favorably with hrHPV physician-
testing. HrHPV mRNA testing may still be more costly than cytology. However, a once-in-a-
lifetime screening using highly sensitive hrHPV self-testing in a low-resource setting with 
infrequent screening may potentially increase the overall screening cost-effectiveness, 
compared with cytology. Our decision analysis nevertheless suggests that, given the current 
information, more data are still required to determine which screening strategy is most 
efficient for our FSW population. 
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CHAPTER 1.  
SPECIFIC AIMS 
Specific Aim 1 
Aim 1.1: To compare the sensitivity and specificity of high-risk HPV (hrHPV) mRNA 
testing of physician- and self-collected specimens to detect cytological high-grade squamous 
intraepithelial lesions or more severe (≥HSIL) in a population of female sex workers (FSW) 
in Nairobi, Kenya aged 18-50 years.  
Hypothesis: We hypothesize that the sensitivity of hrHPV mRNA testing of physician-
collected specimens for ≥HSIL would be higher than that of self-collected specimens. 
Specificity of hrHPV mRNA testing of physician- and self-collected specimens would be 
similar.  
Aim 1.2: To examine the risk factors for hrHPV mRNA positivity in physician- and self-
collected specimens in our population of FSW in Kenya.  
 
Specific Aim 2 
Aim 2.1: To estimate the bounds of sensitivity and specificity (and corresponding 95% 
confidence interval, CI) of hrHPV mRNA testing of physician- and self-collected specimens 
for histological cervical intraepithelial neoplasia 2 or more severe (≥CIN 2) for our FSW 
population in Kenya. 
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Specific Aim 2.2: To evaluate the potential efficiency (measured as number of colposcopies 
required to detect one case of ≥CIN 2) of a once-in-a-lifetime cervical cancer screening in 
our population of FSW in Kenya. We consider three different screening strategies: 
conventional cytology, hrHPV mRNA testing of physician- and self-collected specimens.  
 
 
 
 
 
 
  
CHAPTER 2.  
BACKGROUND AND SIGNIFICANCE 
Human Papillomavirus and Cervical Cancer  
Invasive cervical cancer (ICC) is the third most common cancer in women 
worldwide, the second most common cancer in women in less-developed countries, and the 
leading cancer in women in sub-Saharan Africa. In Eastern Africa, the estimated annual 
incidence of ICC is still the highest in the world (43/100,000) (1). 
Human papillomavirus (HPV) is one of the most common sexually transmitted 
infections (STIs) worldwide. HPV infection of the cervix is well established as the primary 
etiologic factor in ICC carcinogenesis (2). In women, HPV is also responsible for other 
anogenital cancers, including vulvar and vaginal cancers (3). The clinical classification of 
HPV types is according to their oncogenic potential. Among the 35 or so HPV types that 
infect the female genital tract, 14 are considered high-risk types (types 16, 18, 31, 33, 35, 39, 
45, 51, 52, 56, 58, 59, 66 and 68 (4). Women with a persistent infection with one of these 
hrHPV types were shown to have increased risk for developing severe cervical dysplasia or 
ICC (4, 5). HPV types 16 and 18 alone accounted for 60-70% of ICC worldwide. Low-risk 
HPV types (types 6, 11, 26, 30, 32, 34, 40, 42-44, 53-55, 57, 61, 64, 67, 69-73, 81-86, 89 and 
JC 9710) on the other hand are weakly associated with ICC and precancer  (6).  
 HPV prevalence among African women ranged from 18%-60%, with typically 
higher rates among HIV-seropositive women (7). In Kenya, prevalence of high-risk HPV 
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(hrHPV) infection was 44% in women attending family planning clinics in Nairobi (mean 
age 35 years, where prevalence of cytologically-confirmed high-grade squamous 
intraepithelial lesion or more severe (≥HSIL) was 7% (8). Among FSW in Mombasa (median 
age 28 years), prevalence of hrHPV infection was 56%, and that of ≥HSIL was 3% (9).  
 
Constraints to Cytology-Based Cervical Cancer Screening 
The lower incidence and mortality of ICC in developed countries is attributed to the 
implementation of effective conventional cytology screening programs (10-13). Such lower 
incidence and mortality rates are, however, not observed in low-resource regions such as 
Eastern Africa (1). Although facilities for opportunistic screening may be available (14), 
there are still insufficient infrastructure and resources to implement and effectively maintain 
screening programs (15). In Kenya in 2001-2002, only 3% of women were estimated to have 
had a Pap smear in the last three years (4% in urban areas, 2% in rural areas) (16), compared 
to 40% in all countries and 19% in less-developed countries (14).  
Potential barriers to seeking a pelvic examination for cervical cancer screening 
include cultural reticence as well as residence in remote areas where healthcare services are 
not easily assessable (15, 17). Often, these barriers result in late use of screening services by 
women at high risk of cervical cancer, or by those already presenting with advanced disease 
(17). Frequent screenings can be costly and satisfactory coverage and follow-up of women 
with abnormal smears for treatment is difficult to attain (18).  
The interpretation of smears is also inconsistent, due to the subjectivity with which 
the smears are read by cytopathologists (18, 19). In the ASCUS-LSIL Triage Study (ALTS), 
a multicenter randomized controlled-trial on management of atypical squamous cells of 
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undetermined significance (ASCUS) and low-grade squamous intraepithelial lesion (LSIL) 
cytological interpretations, the quality reviewer interpretation of LSIL concurred with the 
original interpretation in 68% of cases, and only 47% for HSIL (19). Finally, Pap smears 
have low sensitivity for detecting ≥CIN 2, with an average sensitivity of 50% (range 30-
80%) (20, 21). 
On the other hand, compared with conventional cytology, molecular HPV testing 
provides an objective test outcome and is highly reproducible (22). High test reproducibility 
has implications on the consistency of the number of true and false positives and negatives 
over time, given that other factors remained constant. The objectivity of test outcome also 
means that the  benefits of screening are not unequally distributed based on the expertise, 
consistency or availability of cytopathologists. HrHPV testing is also more sensitive at 
detecting ≥CIN 2, although generally less specific, compared with conventional cytology 
(23). Higher sensitivity means higher negative predictive value (NPV) for ≥CIN 2 over a 
longer period of time, as risk of developing ≥CIN 2 is low following a negative hrHPV test 
result, thus potentially allowing for decreased number of screening visits and cost (24). The 
lower specificity of hrHPV testing compared with conventional cytology is because most 
HPV infections are transient, and only a minority of women will develop high-grade lesions 
or more severe (25). 
Although prophylactic HPV vaccines are currently available for primary prevention 
of oncogenic HPV types (26, 27), secondary prevention by way of effective screening will 
remain an essential component of screening programs (28). Screening is especially relevant 
in low-resource countries such as Kenya, where screening strategies adopted in more 
developed countries may not be feasible due to logistical and cost issues (28-30). Therefore, 
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alternative screening methods such as HPV testing, which is less subject to inconsistencies 
and potentially allows for larger intervals between screenings, should be considered (31-35). 
 
High-risk HPV mRNA Testing 
In previous studies from Europe and North America, the sensitivity of HPV DNA 
testing to detect ≥CIN 2 was far superior to that of conventional cytology (96% versus 53%), 
although somewhat less specific (91% versus 96%) (23). Recent evidence show that 
molecular HPV testing based on mRNA detection could improve specificity for ≥CIN 2, 
compared with DNA detection (36).  
HPV infection establishes itself at the basal epithelium of the cervix (37). Here, the 
early proteins E6 and E7 are expressed at low levels for viral genome maintenance and cell 
proliferation. As differentiation of the cells of the basal epithelium occurs, the HPV virion 
undergoes genome amplification, virus assembly and eventual release. Expression patterns of 
the virion also shift from early to late genes. Should genetic or epigenetic changes occur to 
cause progression to precursor lesions, the expression of E6/E7 is deregulated, resulting in 
the overexpression of these E6/E7 oncogenes. The E6/E7 mRNA expression of hrHPV types 
is thus vital to the development and progression of ICC (38). HrHPV E6/E7 mRNA 
overexpression could therefore be a more specific marker of precursor lesions which 
potentially warrants further medical attention, compared with hrHPV DNA, since the latter 
may also be found in low- and medium-grade lesions which could be due to a transient HPV 
infection. The hrHPV mRNA assay used in the present study detects HPV E6/E7 mRNA 
from 14 high-risk HPV types (36).  
7 
 
Three population-based studies, from France (39), Canada (35) and China (40), have 
so far been conducted to compare the performance of hrHPV mRNA testing with that of 
hrHPV DNA testing (Table 2.1). In these studies, the hrHPV mRNA testing had comparably 
high sensitivity for the detection of ≥CIN 2 compared with hrHPV DNA testing. HrHPV 
mRNA testing also appeared to be generally more specific than hrHPV DNA testing for the 
detection of ≥CIN 2. Similar sensitivity and higher specificity of hrHPV mRNA testing 
compared with that of hrHPV DNA testing for ≥CIN 2 have also been observed in women 
referred for colposcopy. 
These data demonstrate the feasibility of hrHPV E6/E7 mRNA testing as a valuable 
biomarker for detecting ≥CIN 2, comparing favorably against the more widely used hrHPV 
DNA testing and cytology. The potential of hrHPV mRNA testing should therefore be further 
explored in variable populations and settings. We are not aware of studies of hrHPV mRNA 
testing as a possible tool for cervical cancer screening in Africa.  
 
Self-Collected Specimens for High-Risk HPV and Cervical Lesion Detection 
HPV testing of self-collected specimens has been demonstrated in previous studies to 
be a viable option for circumventing the barriers to cytology- based screening programs, such 
as the need for an initial pelvic examination (18, 28, 41-43). A meta-analysis of 18 studies 
found a high level of agreement (kappa statistic,    0.66; 95% CI: 0.50-0.82) between self- 
and physician- collected specimens for the detection of hrHPV DNA (44). The sensitivity 
and specificity of hrHPV testing of self-collected specimens (hrHPV self-testing) to detect 
≥CIN 2 differed by population and country (Table 2.2).  
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In previous studies, sensitivity of hrHPV testing of physician-collected specimens 
(hrHPV physician-testing) to detect ≥CIN 2 ranged from 82 to 97%, while that of self-
collected specimens ranged from 49 to 92% (Table 2.2). Specificity ranged from 52 to 92% 
using physician-collected specimens, and 53-89% using self-collected specimens. In all 
previous studies, sensitivity of hrHPV physician-testing for ≥CIN 2 was generally higher 
than that of self-testing. Specificity, however, appeared similar in hrHPV physician- and self-
testing across all studies.  
Four previous studies have evaluated hrHPV physician- and self-testing (15, 45-47) in 
African populations. Only one of these studies, conducted on previously unscreened women 
from South Africa, compared hrHPV physician- and self-testing to detect ≥CIN 2 (47) (Table 
2.2). In this study, the sensitivity of hrHPV self-testing for ≥CIN 2 was similar to that of 
conventional cytology (66% and 68%, respectively), but lower than that of physician-testing 
(84%). Specificity of hrHPV physician- and self-testing, as well as of conventional cytology 
for ≥CIN 2 were similar (83%, 85% and 88%, respectively).  
Acceptability of self-collection has been surveyed (15, 28, 48, 49). In Rakai, Uganda, 
women favored self-collection performed during home visits over collection through a pelvic 
examination (>85% versus 50% acceptability) (15, 28). Self-collection was also generally 
accepted in Thailand and China, although some women had reservations about the safety of 
the device (48, 49).  
 
Benefits and Cost Implications of Different Cervical Cancer Screening Strategies in 
Low-Resource Settings 
Randomized controlled trials provide the most accurate estimate of screening efficacy 
of various cervical cancer screening strategies. However, these trials are expensive and 
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require screening of large populations to generate a measurable effect. Also, these trials may 
not be able to adequately assess all types screening strategies (50). Simulation modeling can 
consider differences in population characteristics, test sensitivity and specificity, costs, and 
benefits of different tests or strategies. Results of modeling can potentially inform specific 
policy questions regarding the optimal cervical cancer prevention strategy for a particular 
setting, as well as the affordability of each setting for a screening strategy and follow-up re-
screening or treatment (50). Relatively few studies have assessed screening costs and benefits 
of different cervical cancer screening strategies, including hrHPV-based testing, in low-
resource countries (51-55), and to date, only one study, from South Africa, has evaluated 
screening costs and benefits of hrHPV self-testing in a low-resource setting (52).  
Direct quantitative comparisons of results of screening benefits and costs from 
different studies are challenging due to model choice and parameter assumptions, as well as 
to the imprecision surrounding the estimates of costs and outcomes (50). Parameters for 
population characteristics, as well as test sensitivity and test specificity may also vary by 
settings. Nevertheless, previous studies on low-resource settings in general found that for 
screening one to three times during a woman’s with screening coverage below 25%, 
improvements in the sensitivity of screening tests will have minimal population impact on 
lifetime cervical cancer risk. However, if high screening coverage rates can be achieved in 
settings with infrequent screening, small changes in test sensitivity (range 65-95%) can 
potentially have a larger impact on lifetime cervical cancer risk and overall screening cost-
effectiveness; changes in specificity (range 70-96%), on the other hand, would have less 
impact. On the other hand, in developed countries, overall screening cost-effectiveness is 
heavily affected by small changes in test specificity, due to greater screening coverage, 
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frequent screening and more aggressive follow-up strategies. Previous studies also found that 
the decision among cytology, hrHPV-based testing, and visual inspection in low-resource 
settings will be most affected by the following factors: whether or not screening and 
treatment can be accomplished in fewer visits, costs required for each test, and test sensitivity 
(50).  
 One challenge of such model based analyses is that they are invariably subject to 
uncertainty (imprecision) in the parameters used as inputs in the model (56). If inadequately 
assessed, such parameter uncertainty can lead to the adoption of a suboptimal screening 
strategy with consequent allocation of limited resources.  
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Table 2.1 Comparison of sensitivity and specificity of the high-risk HPV mRNA and high-risk HPV DNA testing to detect ≥CIN 2 
Reference Country Population 
Mean/ 
median 
age  
N 
Sensitivity of hrHPV testing  
for ≥CIN 2 (%)1 
(95% CI) 
Specificity of hrHPV testing  
for ≥CIN 2 (%)1 
(95% CI) 
HrHPV mRNA HrHPV DNA
 
HrHPV mRNA HrHPV DNA
 
Monsonego 
(2011) (39) 
France 
Population- 
based 
20-65 4,429 
92 
(86-98) 
97 
(93-100) 
92 
(91-93) 
86 
(85-87) 
         
Ratnam 
(2011) (35) 
Canada 
Population-
based 
36 1,373 
100 
(56-100) 
100 
(56-100) 
88 
(87-90) 
85 
(83-87) 
         
Wu 
(2010) (40) 
China 
Population-
based 
35 2,095 
100 
(87-100) 
89 
(71-98) 
91 
(90-92) 
85 
(83-86) 
         
Castle 
(2007) (37)
 2
 
USA 
Clinical 
specimens 
NA 527 
92 
(85-97) 
92 
(85-97) 
54 
(49-59) 
47 
(42-52) 
         
Ovestad 
(2011) (57)
3
 
Norway Referral 37 528 
98 
(89-100) 
100 
(93-100) 
38 
(27-49) 
18 
(10-28) 
         
Waldstrom 
(2011) (58)
2
 
Denmark Referral 42 325 
88 
(75-95) 
94 
(83-99) 
78 
(73-83) 
64 
(58-70) 
         
Clad 
(2011) (59) 
Germany Referral NA 424 
92 
(88-95) 
91 
(87-94) 
75 
(68-81) 
61 
(54-68) 
         
Reuschenbach 
(2010) (60) 
Germany Referral 36 205 
92 
(85-96) 
93 
(87-97) 
65 
(53-76) 
56 
(44-67) 
         
Dockter 
(2009) (36) 
France Referral NA 753 
91 
(85-95) 
95 
(90-98) 
56 
(52-60) 
47 
(43-51) 
         
Szarewski 
(2008) (61) 
UK Referral 30 949 
95 
(92-97)  
100 
(98-100) 
42 
(38-46) 
28 
(25-32) 
1
1
 
 
12 
 
Table 2.1 continued 
 
HrHPV: high-risk human papillomavirus; ≥CIN 2: cervical intraepithelial neoplasia 2 or more severe; CI: confidence interval; NA: not available 
1
Unless otherwise indicated, hrHPV mRNA testing was performed using the APTIMA HPV Assay (Hologic Gen-Probe, CA), which detects 14 hrHPV types 
(16,18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 66 and 68) (36), and hrHPV DNA testing was performed using the Hybrid Capture 2 High-Risk HPV DNA Test 
(Qiagen, CA), which detects 13 hrHPV types (16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59 and 68) (62) 
2
HrHPV DNA testing was performed using the Linear Array HPV Genotyping Test (Roche Diagnostics, IN), which detects 13 hrHPV types (16, 18, 31, 33, 35, 
39, 45, 51, 52, 56, 58, 59 and 68) and 24 low-risk HPV types (6, 11, 26, 40, 42, 53, 54, 55, 61, 62, 64, 66, 67, 69, 70, 71, 72, 73,81, 82, 83, 84, IS39 and CP6108) 
(63) 
3
HrHPV DNA testing was performed using the Amplicor Human Papillomavirus Test (Roche Diagnostics, IN), which detects 13 hrHPV types (16, 18, 31, 33, 
35, 39, 45, 51, 52, 56, 58, 59 and 68) (63) 
 
 
 
 
 
 
 
 
 
 
 
 
1
2
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Table 2.2 Comparison of sensitivity and specificity high-risk HPV DNA testing of physician- and self-collected specimens to detect ≥CIN 2 
Reference Country Population 
Mean/ 
median 
age 
N 
Sensitivity of hrHPV DNA testing  
for ≥CIN 2 (%)1 
(95% CI) 
Specificity of hrHPV DNA testing  
for ≥CIN 2 (%)1 
(95% CI) 
Physician-
collection 
Self- 
collection 
Physician-
collection 
Self- 
collection 
Belinson  
(2003) (64) 
China Population-
based 
41 8,497 
97 
(95-99) 
87 
(84-91) 
80 
(79-81) 
77 
(76-78) 
         
Salmeron  
(2003) (18) 
Mexico Population-
based 
41 1,147 
93 
(86-97) 
71 
(61-80) 
92 
(91-92) 
89 
(89-90) 
         
Wright  
(2000) (47) 
South 
Africa 
Previously 
unscreened 
women 
39 1,365 
84 
(73-98) 
66 
(53-77) 
81 
(80-85) 
81 
(79-83) 
         
Bhatla  
(2009) (28) 
India Women with 
gynecological 
complaints 
36 546 
90 
(81-99) 
80 
(68-92) 
92 
(89-94) 
88 
(85-91) 
         
Garcia  
(2003) (65)
2
 
Arizona, 
Mexico, 
Peru 
Women at 
colposcopy 
clinic 
37 334 
82 
(75-90) 
49 
(39-59) 
67 
(61-73) 
73 
(52-79) 
         
Sellors 
 (2000) (42) 
Canada Women at 
colposcopy 
clinic 
32 200 
98 
(91-100) 
86 
(75-94) 
52 
(44-61) 
53 
(45-62) 
         
Hillemanns  
(1999) (41) 
Germany High-risk 
women 
NA 247 
92 
(81-98) 
92 
(81-98) 
72 
(66-78) 
61 
(55-68) 
HrHPV: high-risk human papillomavirus; ≥CIN 2: cervical intraepithelial neoplasia 2 or more severe; CI: confidence interval 
1
Unless otherwise indicated, hrHPV DNA testing was performed using the Hybrid Capture 2 High-Risk HPV DNA Test (Qiagen, CA), which detects 13 hrHPV 
types (16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59 and 68) (62) 
2
HPV DNA testing performed by polymerase chain reaction (PCR) amplification using the PGMY 09/11 L1 consensus primer system, followed by detection of 
27 HPV types (6, 11, 16, 18, 26, 31, 33, 35, 39, 40, 42, 45, 51-59, 66, 68, 73, 82, 83 and 84) (65) 
1
3
 
 
CHAPTER 3. 
METHODS 
Study design 
Study population and recruitment process 
Between August 2009 and March 2011, FSW attending the Korogocho clinic for 
sexually transmitted diseases in Nairobi were invited to participate in a cervical cancer 
screening study. The clinic, jointly managed by the University of Nairobi, provides medical 
care including free cervical cancer screening and treatment for sexually transmitted 
infections (STIs) for FSW in the Korogocho slum area. The clinic also provides counseling 
on the risks of commercial sex work and ways by which these risks may be reduced.   
Women were informed of the study by community peer leaders during “baraza” 
public meetings. Potential participants were advised that participation was completely 
voluntary, and that their care at the clinic would not be affected should they choose to decline 
participation. Participants must be between 18-50 years of age. Women were not eligible if 
they had undergone hysterectomy or were in the second trimester of pregnancy or later. A 
total of 350 FSW aged 18-49 years provided written informed consent and were subsequently 
enrolled.  
 
Specimen collection and processing 
At the clinic during screening, participating women were administered a 
questionnaire to collect sociodemographic, reproductive, and sexual behavior data. Then, 
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each participant in private self-collected a cervico-vaginal specimen for hrHPV mRNA 
testing, using the APTIMA Cervical Specimen Collection and Transport cytobrush (Hologic 
Gen-Probe, San Diego, CA) according to pictorial instructions. The cytobrush was then 
swirled in the APTIMA specimen transport medium (STM) and discarded.  The participant 
then underwent a pelvic examination, during which a physician collected one cervical sample 
for hrHPV mRNA testing, using a Cervex-Brush
 
(Rovers Medical Devices, The 
Netherlands), which was then swirled in the PreservCyt medium (Hologic Gen-Probe, San 
Diego, CA) and discarded. The physician collected a second cervical sample to conduct a 
conventional Pap smear. The physician- and self-collected specimens were stored at -20ºC 
until their transport to Hologic Gen-Probe in San Diego for hrHPV mRNA and STI testing. 
Blood samples were also drawn from each participant for HIV testing and CD4 count 
assessment in the University of Nairobi.  
 
HrHPV mRNA testing  
HrHPV mRNA testing of physician- and self-collected specimens was conducted 
using the APTIMA HPV Assay (Hologic Gen-Probe, San Diego, CA) by Hologic Gen-Probe 
in San Diego, according to manufacturer’s instructions, without knowledge of the Pap smear 
or other study results. The APTIMA HPV Assay is a qualitative nucleic acid amplification 
test which detects E6/E7 mRNA of 14 hrHPV types (16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 
58, 59, 66, 68), but does not identify the HPV type. The assay involves three main steps, all 
taking place in a single tube. First, target mRNA capture by target-specific oligomers linked 
to magnetic microparticles; second, amplification of the isolated target mRNA using 
Transcription Mediated Amplification (TMA); third, detection of the amplification products 
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by chemiluminescent-labeled probed in the Hybridization Protection Assay (HPA). The 
hybridized probe signals are then measured in relative light units (RLU). An internal control 
added to all samples at the target capture step minimizes the risk of false-negative results 
(66).  
Before specimen testing, physician-collected specimens in PreservCyt solution were 
transferred to a tube containing APTIMA STM (Self-collected specimens were already in 
APTIMA STM). The APTIMA STM lyses the cells, releasing mRNA, and protects them 
from degradation.  When the APTIMA HPV Assay is performed, the Assay captures only 
single-stranded nucleic acids to ensure that only hrHPV mRNA, but not DNA, is detected. 
The sequence-specific regions of the capture oligomers hybridizes to specific regions of the 
target hrHPV mRNA. The capture oligomer-hrHPV mRNA complex is then captured out of 
solution by lowering the temperature of the reaction to room temperature. The capture 
oligomer also contains a string of deoxyadenosine residue. The lowering of the temperature 
allows hybridization between the deoxyadenosine region on the capture oligomer and the 
poly-deoxythymidine molecules attached to magnetic particles. The captured target hrHPV 
mRNA bound to the magnetic particles are pulled to the side of the reaction tube by magnets. 
The supernatant is aspirated, and the particles are washed to remove residual specimen that 
potentially act as amplification inhibitors (66).  
In the second step of the APTIMA HPV Assay, the hrHPV mRNA is amplified using 
TMA. TMA is a transcription-based nucleic acid amplification method which uses two 
enzymes, namely the MMLV reverse transcriptase and T7 RNA polymerase.  The MMLV 
reverse transcriptase generates a DNA copy of the target hrHPV mRNA sequence, which 
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contained a promoter sequence for T7 RNA polymerase. From the DNA copy template, T7 
RNA polymerase generates multiple copies of hrHPV mRNA amplicon (66).  
In the third step, the hrHPV mRNA amplicon are detected by HPA, using single-
stranded nucleic acid probes complementary to the amplicon, and which contain 
chemiluminescent labels. These labeled probes hybridize to the amplicon. Hybridized probes 
are differentiated from unhybridized ones using the Selection Reagent, which inactivates the 
label on the unhybridized probes (66).   
Light emitted from the labeled RNA-DNA hybrids is measured as photon signals in a 
luminometer and reported as RLU. Results of the assay are interpreted based on the analyte 
signal-to-cutoff (S/CO). An internal control, added during the target capture, monitors the 
target capture, amplification and detection steps. The signal emitted by the internal control is 
distinguished in each step from the HPV signal by the different light emission kinetics from 
probes with different labels. The hrHPV mRNA amplicon is detected using probes with 
slower light emission (glower), while the internal control amplicon is detected using a probe 
with a more rapid light emission (flasher). HrHPV mRNA testing results are interpreted as 
positive, negative or invalid, as determined by the internal control RLU and the analyte S/CO 
(Table 3.1) (66).  
A run of the APTIMA HPV Assay is invalidated and subsequently repeated when any 
of the following occurred: more than one invalid negative calibrator replicate, more than one 
invalid positive calibrator replicate, an invalid negative control or an invalid positive control. 
A negative calibrator is buffered solution, a positive calibrator non-infectious HPV 16 in 
vitro transcript at 1,000 copies per mL in buffered solution, a negative control lysed, 
inactivated HPV-negative cultured cells in buffered solution and positive control lysed, 
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inactivated HPV-negative and HPV-positive cultured cells at 25 cells per mL in buffered 
solution (66). 
 
STI testing  
The physician- and self-collected specimens were also tested for Chlamydia 
trachomatis and Neisseria gonorrhoeae with the APTIMA Combo 2 assay, for Trichomonas 
vaginalis with the APTIMA TV assay and for Mycoplasma genitalium with the APTIMA 
research use only assay, using the same target capture, TMA and HPA steps as hrHPV 
mRNA detection. STI testing was also performed according to the manufacturer’s 
instructions, without knowledge of the Pap smear or other study results. Serum was tested for 
HIV antibodies by enzyme-linked immunosorbent assay (ELISA), with positive results 
confirmed by a second ELISA. Peripheral blood CD4 cells were enumerated for HIV-
seropositive women.  
 
Cervical cytology 
Cytological smears were evaluated at the University of Nairobi and classified 
according to the 2001 Bethesda System (TBS 2001) for cervical cytology. All smears were 
independently read by two cytopathologists blinded to HPV and STI testing results. For 
discrepant cases, the final diagnosis was made based on the consensus of the reviewing 
cytopathologists. Study participants were notified of their Pap smear results two weeks after 
their screening visit. Women with LSIL or ASCUS were instructed to undergo a repeat 
cytology four months later. Women with HSIL or atypical squamous cells of undetermined 
significance with possibility of high-grade changes (ASCUS-H) were immediately referred to 
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a colposcopy-directed biopsy. In the event of histological ≥CIN 2, women received standard 
care and treatment at Kenyatta National Hospital. Women who had <CIN 2 were considered 
disease negative for statistical analyses.  
 
Statistical methods 
For specific aim 1.1: Sensitivity and specificity hrHPV mRNA physician- and self-testing 
specimens for ≥HSIL 
Of the 350 FSW recruited, 6 women were missing at least one hrHPV testing result 
(specimens missing for 1 woman, self-collected specimens from 5 women invalid for hrHPV 
mRNA testing) and were excluded from subsequent analyses, resulting in a final sample size 
of 344. Median unbiased estimates and their mid-P 95% confidence intervals (CI) were 
computed for sensitivity, specificity, positive predictive value (PPV) and negative predictive 
value (NPV) of hrHPV mRNA testing of physician- and self-collected specimens for the 
detection of ≥HSIL (67).  
 
For specific aim 1.2: Risk factors for hrHPV positivity in physician- and self-collected 
specimens  
Potential risk factors for hrHPV positivity in physician- and self-collected specimens 
were determined, and directed acyclic graphs (DAG) (68) were constructed and analyzed 
with online software (69) to identify minimally sufficient sets of adjustment variables to 
reduce confounding in binomial regression estimates of the prevalence difference of hrHPV 
positivity between categories of potential risk factors. Agreement between hrHPV positivity 
in physician- and self-collected specimens was measured by the kappa statistic. Risk factors 
analyses of hrHPV positivity in physician- and self-collected specimens were restricted to 
women with normal cervical cytology.  
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For specific aim 2.1: Estimation of bounds of sensitivity and specificity of hrHPV testing for 
≥CIN 2 
Using data on sensitivity and specificity of hrHPV testing for ≥HSIL from our FSW 
study (70) and those of ≥HSIL for ≥CIN 2 from the South African study (47), we estimated 
sensitivity and specificity bounds of hrHPV physician- and self-testing in our study of FSW 
for ≥CIN 2 detection. The estimation is described in detail in the Appendix.  
 
For specific aim 2.2 
A. Decision model  
 We developed a decision model using TreeAge Pro
TM
 2012 (TreeAge Software Inc., 
Williamstown, MA, USA) to estimate the potential efficiency of a once-in-a-lifetime cervical 
cancer screening among Kenyan FSW using three screening strategies: conventional 
cytology, hrHPV physician- and self-testing (Figure 1). Screening efficiency was defined as 
the number of colposcopies required to detect one case of ≥CIN 2. This definition was not 
based on total screening cost, as we did not have the resources to estimate costs. 
Furthermore, recommendations of screening strategy need not necessarily be based on cost-
effectiveness findings (71). Colposcopy referrals were used as a surrogate for screening 
program cost in our analysis. We also assume that the cost of each screening test is 
approximately equivalent. We constructed a decision model by which women who had 
≥HSIL at cytological screening or who tested hrHPV mRNA positive in either the physician- 
or self-collected specimens were referred to colposcopy. We modeled whether a woman with 
or without ≥CIN 2 would be referred for colposcopy, under each screening strategy.  
 
 
21 
 
B. Model parameters  
 We obtained estimates of population age distribution, HIV prevalence and of the 
sensitivity and specificity of hrHPV physician- and self-testing for ≥HSIL detection from our 
FSW study in Kenya (70). We obtained estimates for sensitivity and specificity of ≥HSIL for 
≥CIN 2 detection from published data on unscreened South African women (median age 39 
years) (47). The prevalence of ≥HSIL was 4.1% (95% confidence interval, CI: 2.3-6.6%) in 
our FSW study (70) and 3.1% (95% CI: 2.3-4.1%) in the South African study (47). 
Prevalence of ≥CIN 2 in the South African study was 4.1% (95% CI: 3.2-3%) (47) .  
Using data on sensitivity and specificity of hrHPV testing for ≥HSIL from our FSW 
study (70) and those of ≥HSIL for ≥CIN 2 from the South African study (47), we estimated 
sensitivity and specificity bounds of hrHPV physician- and self-testing for ≥CIN 2 detection 
in our study of FSW. The estimation is described in detail in the Appendix.  
We parameterized sensitivity as a function of specificity and of the diagnostic odds 
ratio (72) to take into account the inverse relationship between sensitivity and specificity. We 
used the ratio of sensitivity of hrHPV physician- to self-testing for ≥HSIL in our FSW study 
to reflect the difference in sensitivity of hrHPV physician- and self-testing for ≥CIN 2. The 
same was done to reflect the different in specificity. The performance of hrHPV physician- 
relative to self-testing for ≥HSIL in our study of FSW was consistent (higher sensitivity with 
physician- compared with self-testing, similar specificity) with that of previous studies 
comparing hrHPV DNA physician- and self-testing for ≥CIN 2 in resource-low settings (18, 
28, 47, 64). 
We ascribed a lognormal distribution to the diagnostic odds ratio of ≥CIN 2 detection 
by conventional cytology (using ≥HSIL as screening threshold). Sensitivity and specificity of 
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hrHPV mRNA testing of physician- and self-collected specimens for ≥CIN 2 were first 
sampled from uniform distributions. We specified the upper and lower limit of these uniform 
distributions with our estimated upper and lower bound for sensitivity and specificity. These 
sampled values were then ascribed a beta distribution, where the mean was the sampled value 
and the standard deviation was the mean of the approximate standard error of the lower and 
upper bound estimate. Parameter estimates and distributions used in our model are shown in 
Table 1.  
 
Monte Carlo simulation 
 Monte-Carlo simulations were performed to calculate the probability of each 
screening strategy being optimal at different levels of willingness-to-pay. Probabilistic 
sensitivity analysis was first performed, by randomly drawing a value from each parameter 
distribution (screening test sensitivity and specificity), thereby allowing for the evaluation of 
the combined uncertainty about the parameters in the model (73). This procedure was 
repeated 10,000 times ( =10,000). 
For each set of parameters drawn, 1,000 observations ( =1,000) were generated to 
account for the random variation in individual-level outcomes (e.g. age, HIV-serostatus and 
whether or not a woman had ≥CIN 2) (74). For each of these trials of  =1,000 observations, 
the number of colposcopies performed and the number of women whose ≥CIN 2 was 
detected by colposcopy were estimated for each screening strategy, and the net benefit (  ) 
is calculated across a range of willingness-to-pay limit.  
In a cost-effectiveness analysis, a cost-effectiveness    of one option (i.e treatment 
or intervention) is compared to another. This cost-effectiveness    is defined as:        
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    (where   is the total cost and   the total effect of each option), and is calculated 
across a range of the decision-maker’s willingness to pay for one unit gain in health outcome, 
 . An option is cost-effective if and only if the    for a given   > 1 (75). In assessing the 
   of different screening strategies for our FSW study,    represents the number of 
colposcopies performed   the number of women whose ≥CIN 2 was detected by colposcopy 
and   the number of colposcopy the decision maker is willing to conduct to detect one case 
of ≥CIN 2.  
For each trial of  =1,000 observations, the screening strategy with the highest    
was identified. The proportion of the =10,000 interations in which a screening strategy had 
the highest    at a given   was then used to construct an acceptability curve for each 
screening strategy by plotting these proportions on the  -axis and the corresponding   on the 
 -axis (Figure 2) (75). Since we defined willingness-to-pay as the number of colposcopies 
willing to conduct to detect one ≥CIN 2, this is also equivalent to the inverse of the positive 
predictive value (PPV) for ≥CIN 2 among women with ≥HSIL or positive hrHPV physician- 
or self-testing result. 
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Table 3.1 Interpretation of APTIMA HPV Assay result for the detection of high-risk HPV 
mRNA (66) in female sex workers, Kenya 
APTIMA HPV 
Assay result 
Criteria 
Positive Analyte S/CO
1
 ≥0.05 
Internal control ≤2,000,000 RLU 
Analyte ≤13,000,000 RLU 
  
Negative Analyte S/CO <0.05 
Internal control ≤2,000,000 RLU 
Internal control ≥ Internal control cutoff2 
  
Invalid Analyte S/CO <0.05 and Internal control < Internal control cutoff 
OR Internal control >2,000,000 RLU 
OR Analyte >13,000,000 RLU 
HPV: human papillomavirus; S/CO: signal-to-cutoff; RLU: relative light unit 
1
Analyte S/CO = analyte RLU/analyte cutoff, where analyte cutoff = (mean analyte RLU of the valid 
negative calibrator replicates) + (0.09 x mean analyte RLU of the valid positive calibrator replicates)  
2
Internal control cutoff=0.5 x (mean internal control RLU of the valid negative calibrator replicates)  
 
 
 
 
 
 
 
 
CHAPTER 4. 
HIGH-RISK HUMAN PAPILLOMAVIRUS mRNA TESTING OF PHYSICIAN- AND 
SELF-COLLECTED SPECIMENS FOR CERVICAL LESIONS DETECTION IN HIGH-
RISK WOMEN, KENYA  
Overview 
Little is known about the performance hrHPV physician- and self-testing or risk 
factors for hrHPV mRNA positivity in physician- versus self-collected specimens. We 
compared the performance of hrHPV mRNA physician- and self-testing to detect ≥HSIL and 
examined risk factors for hrHPV mRNA positivity in FSW in Nairobi. 
From 2009-2011, 344 FSW participated in this cross-sectional study. Women self-
collected a cervico-vaginal specimen. A physician conducted a pelvic examination to obtain 
a cervical specimen. Physician- and self-collected specimens were tested for hrHPV mRNA 
and sexually transmitted infections using APTIMA nucleic acid amplification assays. 
Cervical cytology was conducted using physician-collected specimens and classified 
according to the Bethesda criteria.  
Overall hrHPV prevalence was similar in physician- and self-collected specimens 
(30% versus 29%). Prevalence of ≥HSIL was 4% (N=15). Overall sensitivity of hrHPV 
mRNA testing for detecting ≥HSIL was similar in physician- (86%; 95% CI=62-98%, 13 
cases detected) and self-collected specimens (79%; 95% CI=55-95%, 12 cases detected). 
Overall specificity of hrHPV mRNA for ≥HSIL was similar in both physician- (73%; 95% 
CI=68-79%) and self-collected (75%; 95% CI=70-79%) specimens. HrHPV mRNA
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positivity in both physician- and self-collected specimens appeared higher in women who 
were younger (<30 years), had Trichomonas vaginalis or Mycoplasma genitalium infections, 
or had >8 years of educational attainment.  
Self-collected specimens for hrHPV mRNA testing appeared to have similar 
sensitivity and specificity as physician-collected specimens for the detection of ≥HSIL 
among high-risk women.  
 
Introduction 
Successful implementation of Papanicolaou (Pap) smear screening programs has 
drastically reduced ICC incidence and mortality in developed countries (11, 13). However, 
Pap screening programs have been difficult to implement in low-resource settings due to 
limited infrastructure and access to trained cytopathologists and clinicians (30). 
Consequently, a region with low screening coverage such as Eastern Africa still has among 
the highest estimated annual incidence of ICC in the world (34/100,000) (1).  
A primary screening approach based on testing for the central etiological risk factor 
for cervical cancer, hrHPV infection, in self-collected specimens could help increase access 
to screening in low-resource settings. hrHPV testing of self-collected specimens can be 
integrated into a two-stage cervical cancer screening process (76). Women with positive 
hrHPV testing result could be re-screened using a second, more specific test (e.g Pap smear, 
visual inspection with acetic acid, colposcopy) or referred directly to treatment (47). As 
primary hrHPV self-testing does not require an initial gynecologic examination, hrHPV self-
testing as an initial screen could be an advantage in low-resource settings if the appropriate 
follow-up of women with positive HPV results can be assured. Furthermore, women’s 
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acceptability of self-collection has generally been positive in various geographical settings 
worldwide (77). 
Very few studies have evaluated hrHPV self-testing testing for cervical cancer 
screening in low-resource settings and, to date, all have used HPV DNA testing (28, 47, 78).  
Recently developed diagnostic testing allows for the detection of hrHPV mRNA, which may 
be a more specific marker than hrHPV DNA for clinically significant disease (39), and has 
not yet been implemented in a high-risk, low-resource setting.  
We present here results comparing the performance of hrHPV mRNA physician- and 
self-testing to detect high-grade cervical lesions in high-risk FSW in Kenya. We also 
examined risk factors for hrHPV mRNA positivity in our population of FSW.  
 
Materials and Methods 
Study population 
From August 2009 to March 2011, FSW attending the Korogocho clinic in Nairobi, 
Kenya were invited to participate in this study to compare the performance of physician- and 
self-collected specimens for cervical cancer screening with hrHPV mRNA testing. The clinic 
provides counseling and medical care including screening and treatment for cervical cancer 
as well as STIs for FSW in the Korogocho slum area. 
Women were informed of the study by community peer leaders during “baraza” 
public meetings. Women were not eligible if they had undergone hysterectomy or were in the 
second trimester of pregnancy or later. A total of 350 FSW aged 18-49 years provided 
written informed consent and were subsequently enrolled.  
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At screening, participating women were administered a questionnaire to collect 
sociodemographic, reproductive, and sexual behavior data. Of the 350 FSW recruited, 6 
women were missing hrHPV mRNA testing results and were excluded from subsequent 
analyses, resulting in a final sample size of 344.  
 
Sample collection and laboratory analyses 
Each woman self-collected a cervico-vaginal specimen using the APTIMA Cervical 
Specimen Collection and Transport cytobrush (Hologic Gen-Probe Incorporated, San Diego, 
CA) according to pictorial instructions. The cytobrush was then swirled in the APTIMA 
specimen transport medium and then discarded.  During a pelvic examination, the physician 
collected one cervical sample from each woman using a Cervex-Brush (Rovers Medical 
Devices, The Netherlands), which was then swirled in the PreservCyt (Hologic Gen-Probe 
Incorporated, San Diego, CA) medium and then discarded. The physician then collected a 
second cervical sample to conduct a conventional Pap smear.  
Cytological smears were evaluated at the University of Nairobi and classified 
according to the 2001 Bethesda System for cervical cytology. All smears were independently 
read by two cytopathologists blinded to HPV and STI testing results. For discrepant cases, 
the final diagnosis was made based on the consensus of the reviewing cytopathologists. 
Study participants were notified of their Pap smear results two weeks after their screening 
visit. Women with LSIL or ASCUS were instructed to undergo a repeat cytology four 
months later. Women with HSIL or ASCUS-H were immediately referred to a colposcopy-
directed biopsy. In the event of histological ≥CIN 2, women received standard care and 
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treatment at Kenyatta National Hospital. Women who had <CIN 2 were considered disease 
negative for statistical analyses.  
 
HPV and STI testing 
The physician- and self-collected specimens were transported to Hologic Gen-Probe 
in San Diego for HPV and STI testing. Laboratory testing for HPV in our study was by the 
APTIMA
 
HPV Assay (Hologic Gen-Probe Incorporated, San Diego, CA) which qualitatively 
detects E6/E7 mRNA of 14 hrHPV types (16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 66, 
68). The hrHPV mRNA assay comprises three main steps, namely target capture, 
transcription-mediated amplification (TMA) of the target, and finally target detection by 
hybridization with complementary probes linked to chemiluminescent labels (66). 
The physician- and self-collected specimens were also tested for Chlamydia 
trachomatis and Neisseria gonorrhoeae with the APTIMA Combo 2 assay, for Trichomonas 
vaginalis with the APTIMA TV assay and for Mycoplasma genitalium with the APTIMA 
research use only assay, using the same target capture, TMA and hybridization steps as 
hrHPV mRNA detection. All assays were performed according to the manufacturer’s 
instructions, without knowledge of the Pap smear or other study results.  
Serum was tested for HIV antibodies by ELISA, with positive results confirmed by a 
second ELISA. Peripheral blood CD4 cells were enumerated for HIV-seropositive women. 
The HIV ELISA and CD4 assays were conducted in University of Nairobi.  
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Statistical analyses 
Agreement between hrHPV positivity in physician- and self-collected specimens was 
measured by the kappa statistic. Median unbiased estimates and their mid-P 95% confidence 
intervals (CI) were computed for sensitivity, specificity, positive predictive value (PPV) and 
negative predictive value (NPV) of hrHPV testing of physician- and self-collected specimens 
for the detection of ≥HSIL (67). Potential risk factors for hrHPV positivity in physician- and 
self-collected specimens were determined, and directed acyclic graphs (DAG) (68) were 
analyzed with online software (69) to identify minimally sufficient sets of adjustment 
variables to reduce confounding in binomial regression estimates of the prevalence difference 
of hrHPV positivity between categories of potential risk factors. All statistical analyses were 
performed using SAS 9.2.  
 
Results 
Participant characteristics 
Overall prevalence of hrHPV was similar in physician- (30%) and self-collected 
specimens (29%) (Table 4.1). HrHPV prevalence in both physician- and self-collected 
specimens was slightly higher in women <30 years than in older women. Prevalence of any 
abnormal cytology (≥ASCUS) in the population was 19%, and was similar in women ≥30 
years (21%) than in younger women (17%). 
 
Performance of hrHPV mRNA testing of physician- and self-collected specimens 
The overall sensitivity of hrHPV physician-testing for ≥HSIL appeared similar to that 
of self-testing (Table 4.2). HrHPV physician-testing detected only 1 ≥HSIL case more than 
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that of self-testing (N=13 versus N=12) (Table 4.3). This ≥HSIL case, which was negative by 
hrHPV self-testing, was also disease negative by histology. Overall specificity for ≥HSIL 
appeared similar in both hrHPV physician- and self-testing (Table 4.2). 
The NPV for hrHPV mRNA testing of physician- and self-collected specimens was 
97-99% overall and in both age groups. The PPV was 12-13% overall, and varied by age 
group, being somewhat lower in women <30 years (9-10%) than in older women (17-18%). 
The agreement between hrHPV physician- and self-testing was  =59% (95% CI: 49-68) 
overall,  =76% (95% CI: 32-100) in women with ≥HSIL and  =55% (95% CI: 45-65) in 
women with <HSIL.  
Of the 15 women with ≥HSIL, 14 underwent colposcopy-directed biopsy. One 
woman could not be traced and was lost to follow-up. Twelve had histological ≥CIN 2, and 2 
were considered disease negative (both had normal histology). Of the 12 ≥CIN 2 cases, 10 
were hrHPV positive in both physician- and self-collected specimens. The remaining 2 ≥CIN 
2 cases were hrHPV negative in both physician- and self-collected specimens.  
 
Risk factors for hrHPV mRNA positivity in physician- and self-collected specimens with 
normal cervical cytology 
Adjusted prevalence differences (APDs) of hrHPV positivity in both physician- and 
self-collected specimens were generally ≤5% (Table 4.4). APD was >5% in women who 
were younger (<30 years), had T. vaginalis or M. genitalium or had more education (>8 
years). In physician-collected specimens, APD was also >5% in women who reported less 
frequent condom use with sexual clients and regular partners, as well as women who charged 
more per transaction. In self-collected specimens, APD was also >5% in HIV-seropositive 
women and in women with CT/GC infection.  
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The 95% confidence limit differences (difference between upper and lower 95% 
confidence limits, CLD) (79) for the APDs were generally between 0.19 and 0.25 (Table 
4.4).  The least precise APD estimates (95% CLD >0.25) in both physician- and self-
collected specimens were those relating to HIV-seropositivity, C.trachomatis/ N. 
gonorrhoeae, T. vaginalis and M. genitalium positivity, to the number of  regular sexual 
partners, and to frequency of condom use with regular sexual partners. 
  
Discussion 
Physician- and self-collection for hrHPV testing demonstrated a high sensitivity for 
the detection of ≥HSIL. HrHPV self-testing in our population of FSW with high hrHPV 
prevalence appeared to have similar sensitivity and specificity for ≥HSIL as that of hrHPV 
physician-testing. We also found that prevalence of hrHPV positivity in both physician- and 
self-collected specimens was somewhat higher in women who were <30 years, had T. 
vaginalis or M. genitalium infection, or had higher educational attainment.   
The prevalence of hrHPV positivity in our study (30%) was lower than that of hrHPV 
DNA positivity in another FSW population in Mombasa (56%) (9) which had higher HIV 
prevalence than in our study. HrHPV positivity in our study was also lower than hrHPV 
DNA positivity in a similar FSW cohort in Nairobi (54%) which had a lower median age (23 
years) than our study (80). Compared with non-FSW populations in Africa, hrHPV positivity 
in our study was higher than hrHPV DNA positivity in studies which had a higher median 
age (47) or lower HIV prevalence (15) than in our FSW study.  
 The overall sensitivity of hrHPV physician- and self-testing for ≥HSIL in our study 
appeared similar, consistent with a previous study comparing HC2 hrHPV DNA testing of 
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physician- and self-collected specimens for ≥CIN 2 (41). However, the small number of 
women with ≥HSIL (N=15) in our study made comparing sensitivity estimates of hrHPV 
physician- and self-testing in our population of high-risk FSW somewhat difficult. Previous 
studies using HC2 hrHPV DNA testing in Africa (47) and in other settings (28, 78) have also 
found higher overall sensitivity for ≥CIN 2 using physician- compared with self-collected 
specimens. Our finding of similar overall specificity of hrHPV testing for ≥HSIL when using 
physician- or self-collected specimens was also consistent with previous studies that used 
HC2 testing (28, 47, 78). 
Prevalence of ≥HSIL in our study (4%) was similar to what was found in other 
African studies (9, 47). We found that prevalence of ≥HSIL in women <30 years in our study 
was similar to that in women ≥30 years (4% versus 5%) and was thus not notably different in 
this group of high-risk FSW in Kenya. The comparability of ≥HSIL detection by hrHPV 
physician- and self-testing in women <30 years in our study (Table 4.3) suggests that self-
collected specimens for hrHPV testing could also be a viable option for cervical cancer 
screening in high-risk FSW populations 18-29 years of age in Kenya.  
 HrHPV self-testing in our study also detected as many ≥CIN 2 cases as did that of 
hrHPV physician-testing. Our results suggest that in low-resource areas where Pap screening 
is not routinely available, hrHPV self-testing can be used to identify high-risk women at high 
risk of ≥CIN 2.   
In both physician- and self-collected specimens, the somewhat higher (APD >0.05) 
and more precise (confidence limits difference ≤0.25) estimates of hrHPV positivity in 
younger women was consistent with earlier findings from FSW populations, where younger 
age was a strong risk factor for hrHPV DNA positivity (81-83). The relatively higher and 
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more precise hrHPV positivity estimates in women who had higher educational attainment 
was, on the other hand, in contrast to previous studies on FSW populations, where lower 
educational attainment strongly predicted hrHPV DNA positivity (81, 84).  
 Women with M. genitalium or T. vaginalis infection also appeared to have higher 
APD of hrHPV mRNA positivity, although the estimates were imprecise (95% CLD range: 
0.38 to 0.49). Nevertheless, higher hrHPV DNA positivity had been found in women with T. 
vaginalis infection in earlier studies (85, 86).  Data on M. genitalium infection as a risk factor 
for HPV infection are scarce. There was no evidence of increased hrHPV DNA positivity 
with M. genitalium infection in women with normal cervical cytology (87). On the other 
hand, among women with abnormal cytology, higher hrHPV DNA positivity was found in 
those who had a mycoplasma infection (88). Inconsistencies between our results and those of 
earlier studies could be due to differences in populations, methods of assessing and 
categorizing variables, hrHPV test (DNA versus mRNA) and sampling variability. 
Our study has several advantages that improved the validity of the comparison of 
hrHPV physician- and self-testing. Firstly all cervical smears were independently read by 
two cytopathologists, followed by consensus of reviewing cytopathologists for discrepant 
cases to ensure accurate cytological diagnoses. Secondly, a woman’s physician- and self-
collection of specimens were performed on the same day, enabling direct comparison of 
hrHPV mRNA testing results of these two sample types.   
.One limitation of our study was that histological results were obtained only for 
women who had cytological ≥HSIL. As women who were Pap smear normal and hrHPV 
positive were not systematically referred to colposcopy, histological ≥CIN 2 could therefore 
not be used as reference standard for evaluating test sensitivity and specificity, due to the 
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potential for verification bias (89). Although cytological ≥HSIL and LSIL often correspond 
to the histologic diagnoses of, respectively, ≥CIN 2 and CIN 1, previous studies estimated 
that at least 70% of ≥HSIL cases and up to 30% of LSIL cases have ≥CIN 2 (90).  
In terms of public health ramifications, our results of the performance of self- versus 
physician-collected specimens for hrHPV testing were from a high-risk population of FSW in 
a resource poor setting, and therefore not necessarily generalizable to lower risk populations. 
Also, one feasibility concern of using self-collected specimens for HPV testing in primary 
screening is that a woman who tested HPV positive may not return for follow-up screening 
or treatment (47). Other commonly reported issues include difficulty in using the brush for 
self-collection or in understanding the instructions, and contamination of the self-collection 
brush (77). Despite potential limitations, findings from a meta-analysis (44) supported an 
increased usage of self-collection in epidemiological studies. Future research should address 
if self-collection will improve screening coverage in underserved women in low-resource 
settings.  
HrHPV self-testing may not be sufficiently specific to be a stand-alone test for 
cervical cancer screening (8). However, consistent with earlier studies (28, 47, 78), our 
findings showed that hrHPV testing, including hrHPV self-testing, have high NPV and can 
sensitively identify high risk women at greatest risk for high-grade lesions without an initial 
gynecologic examination. The limited resources may then be channeled into clinical follow-
up such as re-screening using a different test of the women who were positive by hrHPV self-
testing based on specific local capacity.  
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Table 4.1 Sociodemographic and sexual behavior characteristics of 344 female sex workers 
in Kenya, 2009-2011 
Characteristic 
Overall 
(N=344)
 
 
Age <30  
(N=197) 
Age ≥30  
(N=147) 
n median or 
% 
median or % median or 
% 
Age (years) 
(range) 
 28  
(18-49) 
25  
(18-29) 
35  
(30-49) 
     
HrHPV mRNA (physician-collection)     
Negative 241 70.1 69.0 71.4 
Positive 103 29.9 31.0 28.6 
     
HrHPV mRNA (self-collection)     
Negative 246 71.5 70.0 73.5 
Positive   98 28.5 30.0 26.5 
     
Cervical cytology     
Normal 279 81.1 82.7 79.0 
ASCUS
a
   14   4.1   3.0   5.4 
LSIL   36 10.5 10.7 10.2 
≥HSIL   15   4.3   3.6   5.4 
     
HIV
b
     
Seronegative 259 76.0 86.3 61.8 
Seropositive   82 24.0 13.7 38.2 
     
CD4 count/mm
3
 
c
 
(range) 
 478  
(152-1391) 
476  
(160-1269) 
492  
(152-1391) 
     
Sexually transmitted infections     
Chlamydia 13   3.8   6.1 0.7 
Gonorrhea   8   2.3   3.0 1.4 
Trichomonas vaginalis 25   7.3   6.1 8.8 
Mycoplasma genitalium 44 12.8 15.7 8.8 
     
Education (years) 
(range) 
 8 
(0-16) 
8 
(0-16) 
8 
(0-15) 
     
Marital status
b
     
Single/never married 150 43.7 54.6 29.2 
Divorced/widowed/separated 190 55.4 44.4 70.1 
Married/cohabitating     3   0.9   1.0   0.7 
     
Age at first sexual intercourse (years) 
(range) 
 16  
(10-25) 
16  
(10-22) 
16  
(10-25) 
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Number of  sexual clients per week  
(range) 
 10  
(2-40) 
10  
(2-40) 
10  
(2-40) 
     
Number of regular sexual partners  
(range) 
 1  
(0-10) 
1  
(0-10) 
1 
 (0-7) 
     
Condom use with sexual clients
b 
    
Most of the time/always 253 73.8 76.0 73.7 
Sometimes/half the time  70 20.4 19.4 21.8 
Never/rarely  20   5.8   4.6   7.5 
     
Condom use with regular sexual 
partners
d
 
    
Most of the time/always  60 24.6 19.5 32.6 
Sometimes/half the time  21   8.6 10.7   5.3 
Never/rarely 163 66.8 69.8 62.1 
     
Charge per transaction (Ksh) 
(range)
e
 
 200  
(50-5,000) 
250 
(50-5,000) 
200 
(50-1,500) 
HrHPV: High-risk HPV; ASCUS: atypical squamous cells of undetermined significance; LSIL: low-
grade squamous intraepithelial lesion; HSIL: high-grade squamous intraepithelial lesion; Ksh: 
Kenyan shillings 
a
Includes atypical glandular cells of undetermined significance (AGUS) (n=2) 
b
Numbers do not add up to total due to missing values: HIV serostatus (n=3); marital status (n=1); 
condom use with sexual clients (n=1) 
c
Among HIV seropositive women (n=82) 
d
Among women with regular sexual partners only (n=244) 
e
200 Ksh is equivalent to 2.50 USD 
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Table 4.2 Performance of high-risk HPV mRNA testing of physician- and self-collected 
specimens for the detection of cytological high-grade cervical lesions in 344 female sex 
workers in Kenya, 2009-2011 
Collection method Sensitivity/specificity 
for ≥HSIL1 
Overall 
(N=344) 
Age <30  
(N=197) 
Age ≥30  
(N=147) 
Physician-collection 
Sensitivity of hrHPV mRNA 
(95% CI) 
86%  
(62, 98) 
84% 
(47, 99) 
86% 
(52, 99) 
    
Specificity of hrHPV mRNA 
(95% CI) 
73% 
(68, 79) 
72% 
(65, 78) 
75% 
(68, 82) 
Self-collection 
 
Sensitivity of hrHPV mRNA 
(95% CI) 
 
79%  
(55, 95) 
 
71%  
(33, 95) 
 
86%  
(52, 99) 
    
Specificity of hrHPV mRNA 
(95% CI) 
75%  
(70, 79) 
73% 
(66, 79) 
78% 
(70, 84) 
HrHPV: high-risk HPV; 95% CI: 95% confidence interval 
1
Median-unbiased estimate of sensitivity and specificity; mid-P 95% CI 
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Table 4.3 High-risk HPV mRNA testing results of physician- and self-collected specimens 
stratified by age and cytology in 344 female sex workers in Kenya, 2009-2011 
Cytology 
HrHPV mRNA test result 
N (hrHPV+ in physician-collection, hrHPV+ in self-collection) 
Overall  Age <30  Age ≥30  
Normal 279 (68, 61) 163 (44, 41) 116 (24, 20) 
ASCUS
a
 14 (8, 10) 6 (3, 4) 8 (5, 6) 
LSIL 36 (14, 15) 21 (8, 9) 15 (6, 6) 
≥HSILb 15 (13, 12) 7 (6, 5) 8 (7, 7) 
Total  344 (103, 98) 197 (61, 59) 147 (42, 39) 
HrHPV: High-risk HPV; ASCUS: atypical squamous cells of undetermined significance; LSIL: low-
grade squamous intraepithelial lesion; HSIL: high-grade squamous intraepithelial lesion 
a
Includes atypical glandular cells of undetermined significance (AGUS) (n=2) 
b
Includes squamous cell carcinoma (SCC) (n=1) 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
40 
 
Table 4.4 Association of potential risk factors with hrHPV mRNA positivity among 279 female sex workers with normal cytology in 
Kenya, 2009-2011 
Risk factors 
Normal 
(N=279)
a
 
HrHPV mRNA positivity  
(physician-collection) 
(N=68) 
HrHPV mRNA positivity  
(self-collection) 
(N=61) 
 n n CP  APD (95% CI)
 b
 n CP  APD (95% CI)
 b
 
Age (years)        
≥30 116 24 0.21  0 20 0.17  0 
<30 163 44 0.27 0.06 (-0.04,0.16) 41 0.25  0.08 (-0.02,0.17) 
        
HIV
c
        
Seronegative 227 53 0.23  0 46 0.20  0 
Seropositive 51 15 0.29  0.01 (-0.17,0.20) 15 0.29  0.11 (-0.08,0.29) 
        
STI
d
        
Chlamydia/gonorrhea        
Negative 261 60 0.23  0 55 0.21  0 
Positive 18 8 0.44  0.01 (-0.29,0.28) 6 0.33  0.10 (-0.18,0.37) 
Trichomonas vaginalis        
Negative 259 60 0.23  0 56 0.22  0 
Positive 20 8 0.40  0.19 (-0.06,0.43) 5 0.25  0.09 (-0.12,0.31) 
Mycoplasma genitalium        
Negative 244 57 0.23  0 51 0.21  0 
Positive 35 11 0.31  0.09 (-0.11,0.29) 10 0.29  0.06 (-0.13,0.25) 
        
Education (years)
 e
        
≤8 208 47 0.23  0 41 0.20  0 
>8 71 21 0.30  0.06 (-0.06,0.19) 20 0.28  0.09 (-0.03,0.20) 
        
Marital status
f
        
Single/never married 122 37 0.30  0 31 0.25  0 
Divorced/widowed/separated 156 31 0.20  -0.09 (-0.20,0.01)  30 0.19  -0.03 (-0.14,0.08) 
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Age at first sexual intercourse 
(years)
g
 
       
≥16 174 44 0.25  0 39 0.22  0 
<16 105 24 0.23 -0.02 (-0.13,0.08) 22 0.21  -0.02 (-0.11,0.08) 
        
Number of sexual clients per week
 e
        
≤10 158 40 0.25  0 34 0.21  0 
>10 121 28 0.23  -0.01 (-0.11,0.09) 27 0.22  0.04 (-0.05,0.14) 
        
Number of regular sexual partners
h
        
≤1 227 54 0.24  0 47 0.21  0 
>1 52 14 0.27 0.02 (-0.11,0.15) 14 0.27  0.05 (-0.08,0.18) 
        
Condom use with sexual clients
i
        
≥Most of the time 202 47 0.23  0 44 0.21  0 
<Most of the time 76 21 0.28  0.06 (-0.06,0.17) 17 0.22  0.01 (-0.09,0.12) 
        
Condom use with regular sexual 
partners
j
 
       
≥Most of the time 43 9 0.21  0 10 0.23  0 
<Most of the time 155 42 0.27  0.12 (-0.02,0.28) 36 0.23  0.05 (-0.10,0.19) 
        
Charge per transaction (Ksh)
 e
        
≤200 160 35 0.22  0 29 0.18 0 
>200 119 33 0.28 0.06 (-0.06,0.16) 32 0.27  0.05 (-0.06,0.16) 
HrHPV: high-risk HPV; STI: sexually transmitted infection; Ksh: Kenyan shillings; CP: crude prevalence; AP: adjusted prevalence; APD: adjusted 
prevalence difference; CI: confidence interval 
a
Analyses restricted to women with normal cervical cytology and valid specimens for hrHPV mRNA testing (n=279) 
b
Each minimally sufficient adjustment set identified by directed acyclic graph (DAG) 
c
One woman missing HIV serostatus; estimates adjusted for age, STI, average number of sexual clients per week, number of regular sexual 
partners, condom use with sexual clients and condom use with regular sexual partners 
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Table 4.4 continued 
 
d
Estimates adjusted for age, other STI, average number of sexual clients per week, number of regular sexual partners, condom use with sexual 
clients and condom use with regular sexual partners  
e
Estimates adjusted for age 
f
One woman missing marital status; the three women presently married were categorized under divorced/widowed/separated; estimates adjusted for 
age 
g
Estimates adjusted for age and education 
h
Estimates adjusted for age and marital status  
i
One woman missing data on condom use with sexual clients; estimates adjusted for age, HIV serostatus, STI, education, marital status  
jAmong women with ≥1 regular sexual partners only (n=198); estimates adjusted for age, HIV serostatus, STI, education, marital status  
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CHAPTER 5. 
IMPACT OF UNCERTAINTY IN RELATIVE TEST PERFORMANCE BETWEEN 
CYTOLOGY, PHYSICIAN- AND SELF-COLLECTED HIGH-RISK HPV TESTING ON 
ESTIMATED SCREENING EFFICIENCY IN KENYA: A SIMULATION 
Overview 
The costs and benefits of each cervical cancer screening strategy must be considered 
to determine the optimal screening strategy for a low-resource setting. We estimated the 
potential efficiency (measured as colposcopies required per ≥CIN 2 detected) of a once-in-a-
lifetime cervical cancer screening among female sex workers (FSW) in Kenya using three 
strategies: conventional cytology, high-risk (hr) HPV physician- and self-testing.  
We estimated bounds of sensitivity and specificity of hrHPV physician- and self-
testing for ≥CIN 2 from our study of FSW in Kenya and from published South African data. 
We constructed a decision model of FSW in Kenya, and performed probabilistic sensitivity 
analyses to identify the proportion of simulations where a given screening strategy was 
optimal at a given “willingness-to-pay” (number of colposcopies willing to conduct to detect 
a case of ≥CIN2) limit. 
The estimated sensitivity bounds for ≥CIN 2 of hrHPV physician-testing  
(53-91%) were similar to those of self-testing (53-99%). The estimated specificity bounds 
were also similar for physician- (71-73%) and self-testing (71-75%). At a willingness-to-pay 
of <15 colposcopies per ≥CIN 2 detected, the probability of cytology being optimal was 
>80%. At a willingness-to-pay of 20-40 colposcopies per ≥CIN 2 detected, the probability of 
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all three strategies being optimal was ≤50%. Above 40 colposcopies per ≥CIN 2 detected, the 
probability of conventional cytology being optimal decreased to 10-20%.  
 At a willingness-to-pay limit of <15 colposcopies per ≥CIN 2 detected, conventional 
cytology was the optimal screening strategy, given the available information. At a higher 
willingness-to-pay limits, the probability that hrHPV testing being optimal exceeded that of 
conventional cytology. However, due to relative imprecision of the sensitivity and specificity 
of hrHPV testing for ≥CIN 2, more data (e.g extending the model to include costs and 
estimated impact of each screening strategy on cervical cancer mortality) is likely required to 
determine which screening strategy is most efficient at higher willingness-to-pay limits.   
 
Introduction 
Cytology-based screening programs effectively prevent invasive cervical cancer 
(ICC) (11). Such programs, however, are generally difficult to implement in low-resource 
regions due to limited access to trained clinicians and cytologists (30). Testing for high-risk 
human papillomavirus (hrHPV) infection, the necessary cause of ICC, could improve the 
sensitivity of screening programs to detect high-grade cervical intraepithelial neoplasia 
(≥CIN 2) and result in a high negative predictive value for ≥CIN 2 (23, 91). Molecular 
hrHPV testing also has greater reproducibility compared with conventional cytology (22).  If 
provided via self-collected specimens, access to screening in low-resource regions could 
potentially be more available. High sensitivity of a screening test must also be balanced 
against test specificity, since a false-positive screening test may lead to colposcopy or even 
treatment, incurring extra costs and exposing the woman to a more invasive procedure (92).  
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Identification of the most efficient screening strategy requires comparison of the 
impact of different screening tests’ sensitivity and specificity for ≥CIN 2 screening benefits 
and costs (74, 93). Here we compare the screening efficiency of three cervical cancer 
screening strategies, as well as the uncertainty surrounding the choice among them, in a 
female sex worker study from Kenya (70). We define screening efficiency as the number of 
colposcopies required to detect a case of ≥CIN 2.  Screening strategies considered are 
conventional cytology, hrHPV testing of physician-collected specimens (hrHPV physician-
test) and that of self-collected specimens (hrHPV self-test).  
We first estimate bounds of sensitivity and specificity of hrHPV physician- and self-
testing for ≥CIN 2 detection from our study of female sex workers (FSW) (70) and other 
published data from South Africa (47). We then identify the optimal screening strategy, in 
terms of screening efficiency at a given “willingness-to-pay” (number of colposcopies 
willing to conduct to detect one ≥CIN 2) limit, for a once-in-a-lifetime cervical cancer 
screening in a female sex worker population in Kenya.  
 
Materials and Methods 
Study population 
The FSW study in Nairobi, Kenya has been previously described (70). Briefly, in 
2009-2011, a total of 343 FSW (median age 28 years) were enrolled in a study to compare 
the performance of hrHPV mRNA testing of physician- and self-collected specimens for the 
detection of cytological high-grade squamous intraepithelial lesion or more severe (≥HSIL). 
Each participating woman first self-collected a cervico-vaginal specimen in a clinical setting 
using standardized illustrations. Next, during a pelvic examination, cervical samples from 
46 
 
each woman were collected by a physician for hrHPV mRNA testing and for conventional 
cytology. Women with ≥HSIL were immediately referred to colposcopy and directed-biopsy 
upon indication. The physician- and self-collected specimens were tested for hrHPV mRNA 
by the APTIMA
 
Assay (Hologic Gen-Probe Incorporated, San Diego, CA).  
 
Decision model  
 We developed a decision model using TreeAge Pro
TM
 2012 (TreeAge Software Inc., 
Williamstown, MA, USA) to estimate the potential efficiency of a once-in-a-lifetime cervical 
cancer screening among Kenyan FSW using three screening strategies: conventional 
cytology, hrHPV physician- and self-testing (Figure 5.1). Screening efficiency was defined 
as the number of colposcopies required to detect one case of ≥CIN 2. This definition was not 
based on total screening cost, as we did not have the resources to estimate costs. 
Furthermore, recommendations of screening strategy need not necessarily be based on cost-
effectiveness findings (71). Colposcopy referrals were used as a surrogate for screening 
program cost in our analysis. We also assume that the cost of each screening test is 
approximately equivalent. We constructed a decision model by which women who had 
≥HSIL at cytological screening or who tested hrHPV mRNA positive in either the physician- 
or self-collected specimens were referred to colposcopy. We modeled whether a woman with 
or without ≥CIN 2 would be referred for colposcopy, under each screening strategy.  
 
Model parameters  
 We obtained estimates of population age distribution, HIV prevalence and of the 
sensitivity and specificity of hrHPV physician- and self-testing for ≥HSIL detection from our 
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FSW study in Kenya (70). We obtained estimates for sensitivity and specificity of ≥HSIL for 
≥CIN 2 detection from published data on unscreened South African women (median age 39 
years) (47). The prevalence of ≥HSIL was 4.1% (95% confidence interval, CI: 2.3-6.6%) in 
our FSW study (70) and 3.1% (95% CI: 2.3-4.1%) in the South African study (47). 
Prevalence of ≥CIN 2 in the South African study was 4.1% (95% CI: 3.2-5.3%) (47) .  
Using data of i) hrHPV testing to detect ≥HSIL and ii) ≥CIN 2 diagnosis in women 
with ≥HSIL from our FSW study (70), as well as iii) cytological testing (≥HSIL) to detect 
≥CIN 2 from the South African study (47), we estimated sensitivity and specificity bounds of 
hrHPV physician- and self-testing for ≥CIN 2 detection in our study of FSW. The estimation 
is described in detail in the Appendix.  
We parameterized sensitivity as a function of specificity and of the diagnostic odds 
ratio (72) to take into account the inverse relationship between sensitivity and specificity. We 
used the ratio of sensitivity of hrHPV physician- to self-testing for ≥HSIL in our FSW study 
to reflect the difference in sensitivity of hrHPV physician- and self-testing for ≥CIN 2. The 
same was done to reflect the different in specificity. The performance of hrHPV physician- 
relative to self-testing for ≥HSIL in our study of FSW was consistent (higher sensitivity with 
physician- compared with self-testing, similar specificity) with that of previous studies 
comparing hrHPV DNA physician- and self-testing for ≥CIN 2 in resource-low settings (18, 
28, 47, 64). 
We ascribed a lognormal distribution to the diagnostic odds ratio of ≥CIN 2 detection 
by conventional cytology (using ≥HSIL as screening threshold). Sensitivity and specificity of 
hrHPV mRNA testing of physician- and self-collected specimens for ≥CIN 2 were first 
sampled from uniform distributions. We specified the upper and lower limit of these uniform 
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distributions with our estimated upper and lower bound for sensitivity and specificity. These 
sampled values were then ascribed a beta distribution, where the mean was the sampled value 
and the standard deviation was the mean of the approximate standard error of the lower and 
upper bound estimate. Parameter estimates and distributions used in our model are shown in 
Table 1.  
 
Monte Carlo simulation 
 Monte-Carlo simulations were performed to calculate the probability of each 
screening strategy being optimal at different levels of willingness-to-pay. Probabilistic 
sensitivity analysis was first performed, by randomly drawing a value from each parameter 
distribution (screening test sensitivity and specificity), thereby allowing for the evaluation of 
the combined uncertainty about the parameters in the model (73). This procedure was 
repeated 10,000 times ( =10,000). 
For each set of parameters drawn, 1,000 observations ( =1,000) were generated to 
account for the random variation in individual-level outcomes (e.g. age, HIV-serostatus and 
whether or not a woman had ≥CIN 2) (74). For each of these trials of  =1,000 observations, 
the number of colposcopies performed and the number of women whose ≥CIN 2 was 
detected by colposcopy were estimated for each screening strategy, and the net benefit (  ) 
is calculated across a range of willingness-to-pay limit.  
In a cost-effectiveness analysis, a cost-effectiveness    of one option (i.e treatment 
or intervention) is compared to another. This cost-effectiveness    is defined as:        
    (where   is the total cost and   the total effect of each option), and is calculated 
across a range of the decision-maker’s willingness-to-pay for one unit gain in health 
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outcome,  . An option is cost-effective if and only if the    for a given   > 1 (75). In 
assessing the    of different screening strategies for our FSW study,    represents the 
number of colposcopies performed,   the number of women whose ≥CIN 2 was detected by 
colposcopy and   the number of colposcopy the decision maker is willing to conduct to 
detect one case of ≥CIN 2.  
For each trial of  =1,000 observations, the screening strategy with the highest    
was identified. The proportion of the =10,000 interations in which a screening strategy had 
the highest    at a given   was then used to construct an acceptability curve for each 
screening strategy by plotting these proportions on the  -axis and the corresponding   on the 
 -axis (Figure 5.2) (75). Since we defined willingness-to-pay as the number of colposcopies 
willing to conduct to detect one ≥CIN 2, this is also equivalent to the inverse of the positive 
predictive value (PPV) for ≥CIN 2 among women with ≥HSIL or positive hrHPV physician- 
or self-testing result.  
 
Results 
Bounds of sensitivity and specificity of hrHPV testing for ≥CIN 2 
The estimated sensitivity bounds of hrHPV physician-testing for ≥CIN 2 (45-91%) in 
our study of FSW were similar to that of self-testing (45-9%). The estimated specificity 
bounds were also similar for physician- (71-74%) and self-testing (73-75%), and were much 
narrower than those of sensitivity (Table 5.2). 
The difference between the upper and lower 95% confidence limits (confidence limit 
difference, CLD) (79) for the true sensitivity of hrHPV testing to detect ≥CIN 2 was similar 
for physician- and self-testing (CLD=0.68 for both hrHPV physician- and self-testing). The 
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CLD of the 95% confidence limit for the true specificity was also similar for physician- and 
self-testing (CLD=0.10 for physician- and CLD=0.11 for self-collected specimens) (Table 
5.2), and are lower than those for sensitivity.  
 
Comparison of screening efficiency and associated uncertainty 
Figure 5.2 shows an acceptability curve: the proportion of simulations that an 
individual screening strategy was optimal (i.e, having the highest     at a given willingness-
to-pay limit. Given the available information, at a willingness-to-pay limit of <15 
colposcopies per case of ≥CIN 2 detected, conventional cytology has >80% probability of 
being optimal. At a willingness-to-pay of between 20 and 30-40 colposcopies per case of 
≥CIN 2 detected, the probability of all three strategies being optimal was between 8-50%. 
Above 40 colposcopies per case of ≥CIN 2 detected, the probability of conventional cytology 
being optimal decreased to between 10-20%. Also, above this willingness-to-pay limit, the 
probability of hrHPV physician-testing being optimal increased to between 55-60%, while 
that of hrHPV self-testing remained at between 25-30%.  
 
Prevalence of ≥CIN 2 by age 
 Using maximum likelihood estimation (Appendix), the estimated prevalence of ≥CIN  
was 4.3% (95% CI: 3.3-5.3%). This prevalence of ≥CIN 2 appeared to vary by age, and 
estimated to be higher among older compared with younger women (>4% in women ≥30 
years, <4% in women <30 years) women (Table 5.3).   
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Discussion 
At a willingness-to-pay limit of <15 colposcopies per case of ≥CIN 2 detected, 
conventional cytology was the optimal screening strategy, for a once-in-a-lifetime cervical 
cancer screening in a population of FSW in Kenya. At a willingness-to-pay limit of between 
20 to 40 colposcopies per case of ≥CIN 2 detected, the probability of any of the three 
strategies being optimal was ≤50%. At a willingness-to-pay limit of >40 colposcopies per 
case of ≥CIN 2 detected, the probability of hrHPV physician-testing being optimal increased 
to between 55-60%, while that of hrHPV self-testing and conventional cytology was between 
15-30%. Our analysis suggests that at relatively higher willingness-to-pay limits, more 
research may be required to determine which screening strategy is most efficient.  
The estimated sensitivity bounds of hrHPV physician-testing for ≥CIN 2 in our 
population of FSW in Kenya were somewhat wide (45-91%). Sensitivity estimates of hrHPV 
mRNA testing for ≥CIN 2 from population-based studies from Canada (35), France (39) and 
China (40) were higher than our estimated bounds (92-100%). Our estimated specificity 
bounds (71-75%) were relatively lower, however, than other population-based estimates (88-
92%) (35, 39, 40). Our lower specificity is likely due to the higher overall hrHPV prevalence 
in our FSW (30%) as compared with previous studies, where overall hrHPV prevalence 
ranged from 10-12% (35, 39, 40). Although specificity of hrHPV testing for ≥CIN 2 will 
decrease with increasing hrHPV prevalence, the PPV for ≥CIN 2 among women positive for 
hrHPV will not decrease (94). Compared with other low-resource settings, the estimated 
≥CIN 2 prevalence in our study of FSW (4.3%, median age 28 years) appeared similar to that 
in South Africa (4.1%, median age 39 years)(47) and China (4.4%, mean age 40 years) (64), 
albeit lower than that in India (7.8%, median age 36 years) (28). 
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HrHPV physician- or self-testing were the optimal screening strategy at higher limits 
of willingness-to-pay (>30 colposcopies to detect one case of ≥CIN 2 for physician-collected 
specimens and >60 self-collected specimens). We are unable, however, to compare our 
results directly with previous cost-effectiveness analyses of different screening strategies due 
to different modeling approaches and outcomes being considered (e.g different definition of 
screening cost) (51, 52, 95). Nevertheless, our finding that a screening strategy with greater 
sensitivity was optimal only at higher willingness-to-pay limits was qualitatively similar to 
previous cost-effectiveness findings, where increased sensitivity was associated with higher 
screening cost relative to benefits (95). Compared with conventional cytology, hrHPV testing 
in our analysis also has a potentially higher sensitivity, but lower specificity to detect ≥CIN 
2, consistent with previous findings comparing hrHPV DNA with conventional cytology (18, 
47). Greater sensitivity unaccompanied by improved specificity can explain our finding that 
hrHPV testing increased only with higher willingness-to-pay limits. Nevertheless, in previous 
analyses on low-resource settings with infrequent screening which accounted for actual 
screening costs as well as the impact of screening on lifetime cancer risk and mortality, even 
small increments in test sensitivity can increase overall screening cost-effectiveness. Changes 
in test specificity, on the other hand, were much less influential on screening cost-
effectiveness (50).  
We defined screening efficiency as the number of colposcopies conducted per ≥CIN 2 
detected, without accounting for the actual cost of screening, thus limiting the comparability 
of our results with other cost-effectiveness data on low-resource regions (51, 52). However, 
the screening strategies considered in this study have already been successfully implemented 
in our population of FSW. Considering the costs and benefits in terms of the number of 
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colposcopies required to detect a case of ≥CIN 2 can inform us of the practicality of 
screening by hrHPV without triage by a more specific test, compared with conventional 
cytology. Furthermore, colposcopies per case of ≥CIN 3 detected was used as the primary 
measure of harm by the American Cancer Society, American Society for Colposcopy and 
Cervical Pathology, and American Society for Clinical Pathology when developing screening 
guidelines, as colposcopies can cause physical discomfort and potentially lead to more 
invasive procedures with greater harms (24).    
 An advantage of our analysis is that since the screening strategies evaluated have 
been successfully employed in our FSW population, we did not have to make assumptions on 
the availability of screening tests and feasibility of implementing a screening strategy. 
Further, as our decision model ascribed a distribution to the input parameters, we accounted 
for the imprecision surrounding not only the sensitivity and specificity of screening tests, but 
also that surrounding the screening outcomes (e.g cytological finding of ≥HSIL or positive 
for hrHPV testing) of individual participants. This allow decisions to be made based on the 
decision maker’s preferred maximum limit for screening cost, in terms of number of 
colposcopies (74, 75, 96).   
This study has several limitations. We found only one African study, from South 
Africa (47), which had complete data on cervical histology stratified by cytology that we 
could use to estimate sensitivity and specificity bounds of hrHPV testing to detect ≥CIN 2. 
The sensitivity and specificity of conventional cytology for ≥CIN 2 in the South African 
study may have differed from those in our FSW study. However, ≥HSIL prevalence in the 
South African study (4.1%, 95% CI: 3.2-5.3%) (47) was similar to that in our FSW study 
(3.1%, 95% CI: 2.3-4.1%) (70). Further, we assumed perfect adherence to follow-up to 
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colposcopy of women with ≥HSIL or positive hrHPV testing results, and, implicitly, 100% 
sensitivity of colposcopy and receipt of appropriate treatment for ≥CIN 2 lesions.  Also, 
given the high hrHPV prevalence in our FSW (70), many women who were hrHPV positive 
and referred to colposcopy may have low-grade cervical lesions, or not have any cervical 
abnormality at all. As a positive screening test result can potentially have emotional impact 
on a woman, the effect of screening strategies on the overall quality of life should also be 
considered in future analyses when comparing screening strategies (95). 
In conclusion, our findings potentially have implications for other low-resource 
settings with a similarly high-risk population as our FSW which are considering a once-in-a-
lifetime screening program. Our estimated specificity of hrHPV testing for ≥CIN 2 was 
somewhat lower than that of conventional cytology. However, previous data found that 
despite a lower specificity, the PPV for ≥CIN 2 among women with hrHPV test positive 
results is likely higher in populations with high hrHPV prevalence and lack of previous 
screening, as is generally the case with most resource-low settings (94). Given the available 
data and the imprecision of sensitivity and specificity estimates of hrHPV testing for ≥CIN 2 
in our analysis, however, our results suggest that further empiric data is needed to determine 
the optimal screening strategy at higher willingness-to-pay limits, and that extension of the 
model to incorporate total costs and estimated impact of each screening strategy on ICC 
mortality is needed. We may then compare the effect of imprecision surrounding estimates of 
costs and mortality to that of test performance, on the efficiency of each screening strategy 
(value-of-information, (97)). Such value-of-information assessment potentially informs us of 
the important areas in which to focus future research and limited research resources.  
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Table 5.1 Parameter estimates, distributions, confidence intervals utilized in the simulation 
model of cervical cancer screening efficiency in female sex workers in Kenya 
CI=confidence interval; CIN=cervical intraepithelial neoplasia; HSIL=high-grade squamous 
intraepithelial neoplasia; hrHPV= high-risk human papillomavirus infection 
1Cytologic threshold of ≥HSIL 
 
Variable Estimate  Distribution 95% CI Reference 
Prevalence of women age ≥30 
years 
43%  Beta 38-48 (70) 
     
Prevalence of HIV-seropositivity      
<30 years 14%  Beta 9-19 (70) 
≥30 years 38% Beta 30-46 (70) 
     
Prevalence of ≥CIN 2      
HIV-seronegative women 2%  Beta 1-5 (98) 
HIV-seropositive women 7%  Beta 3-15 (98) 
     
Conventional cytology
1
     
Sensitivity for ≥CIN 2 52%  Beta 38-65 (47) 
Specificity for ≥CIN 2 99%  Beta 98-100 (47) 
     
Ratio of sensitivity of self- to 
physician-collected hrHPV 
mRNA testing for ≥CIN 2 
    
Sensitivity 1.08 Lognormal 0.79-1.50 Assumption (70) 
Specificity 0.98 Lognormal 0.90-1.08 Assumption (70) 
     
Follow-up of women with  
abnormal results  
100%   Assumption 
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Table 5.2 Estimated bounds of sensitivity and specificity of high-risk HPV mRNA testing of physician- and self-collected specimens 
for ≥CIN 2 detection among female sex workers in Kenya 
Specimen type 
Sensitivity of hrHPV mRNA for ≥CIN 2  Specificity of hrHPV mRNA for ≥CIN 2 
Lower 
bound 
SE 
Upper 
bound 
SE 95% CI
1
  
Lower 
bound 
SE 
Upper 
bound 
SE 95% CI
2
 
Physician-collected 
specimens 
45% 0.08 91% 0.06 32-100%  71% 0.02 74% 0.03 68-78% 
            
Self-collected  
Specimens 
45% 0.08 91% 0.06 32-100%  73% 0.02 75% 0.02 68-79% 
HrHPV=high-risk human papillomavirus; CIN= cervical intraepithelial neoplasia; SE=standard error; 95% CI= 95% confidence interval  
1
Critical value    ⁄  used to calculate the 95% CI was 1.645 
2
Critical value    ⁄  used to calculate the 95% CI was 1.750 
 
 
 
 
 
 
 
 
 
 
 
5
6
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Table 5.3 Approximate prevalence of ≥CIN 2, stratified by age, among female sex workers in 
Kenya 
Age (years) Prevalence of ≥CIN 2 
<25 3.5% 
25-29 3.7% 
30-39 4.2% 
≥40 4.5% 
CIN=cervical intraepithelial neoplasia 
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Figure 5.1 Decision model for cervical cancer screening in female sex workers in Kenya.  
A woman undergoes a once-in-a-lifetime cervical cancer screening by cytology, high-risk 
human papillomavirus (hrHPV) physician- or self-testing. All women are referred to 
colposcopy in the event of cytological high-grade squamous intraepithelial lesions or more 
severe (≥HSIL) or positivity for hrHPV physician- or self-testing. Inputs for age, HIV, 
≥HSIL as well as sensitivity and specificity of hrHPV physician- and self-testing for ≥HSIL 
are obtained from our female sex workers study in Kenya (70). Inputs for histological 
cervical intraepithelial neoplasia or more severe (≥CIN 2) prevalence stratified by HIV-
serostatus, as well as the sensitivity and specificity of ≥HSIL for ≥CIN detection are from 
published data from South Africa (47, 98). Inputs for sensitivity and specificity of hrHPV 
physician- and self-testing for ≥CIN 2 are estimated from our female sex workers study and 
from published data from South Africa (47). A true-positive outcome is when a screening test 
correctly identifies a woman with true ≥CIN 2 for colposcopy (a screening benefit). The 
false-positive outcome is referring a woman with <CIN 2 to colposcopy (a screening burden).  
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Figure 5.2 Acceptability curve for the three cervical cancer screening scenarios.  
Each line shows the proportion of the 10,000 iterations (each with 1,000 women) in which 
that screening strategy had the highest net benefit (  ) at a value of willingness-to-pay. 
Inputs: Cytology=conventional cytology, sensitivity 52% (95% CI: 38-65%) and specificity 
99% (95% CI: 98-100%) for ≥CIN 2; Physician-collection=high-risk (hr) HPV physician-
testing, sensitivity bounds 45-91% (95% CI: 32-100%) and specificity bounds 71-74% (95% 
CI: 68-78%) for ≥CIN 2; Self-collection=hrHPV self-testing sensitivity bounds 45-91% 
(95% CI: 32-100%) and specificity bounds 73-75% (95% CI: 68-79%) for ≥CIN 2.  
 
 
 
 
 
 
 
 
 
CHAPTER 6. 
CONCLUSIONS 
Summary of Findings  
Sensitivity and specificity of hrHPV self-testing for ≥HSIL were similar to those of 
physician-testing in our population of FSW. Our finding of similar sensitivity was contrary to 
our hypothesis, where we anticipated higher sensitivity when using physician- compared with 
self-collected specimens. Although our estimates are imprecise, they nevertheless suggest 
that hrHPV self-testing has the potential to offer a simple, private and convenient self-test 
which can help increase access to screening in low-resource regions.  
The estimated sensitivity bounds of hrHPV physician-testing for ≥CIN 2 (49-100%) 
for our FSW population were similar to those of self-testing (43-96%). Specificity bounds 
were also similar for physician- (71-74%) and self-testing (72-75%), and were narrower than 
those of sensitivity. We believe that our lower estimated specificity bounds compared with 
previous studies (88-92%) (35, 39, 40) was due to our FSW having a higher overall hrHPV 
prevalence (30%) than that in previous studies (10-12%) (35, 39, 40). A previous systematic 
review found specificity of hrHPV testing for ≥CIN 2 to decrease with increasing hrHPV 
prevalence (94). Nevertheless, our finding of lower specificity should not be a deterrent to 
use of hrHPV-based screening in settings with high hrHPV prevalence. The reason is that the 
PPV for ≥CIN 2 among women with hrHPV test positive results is likely higher in 
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populations with high hrHPV prevalence and lack of screening, as in most low-resource settings 
(94). 
Presenting our findings of the decision analysis in the form of an acceptability curve 
(Figure 5.2) allows decisions to be made based on the decision maker’s preference for the 
maximum limit of screening cost (willingness-to-pay). We found that at a lower willingness-to-
pay limit of <15 colposcopies per case of ≥CIN 2 detected, conventional cytology was the 
optimal screening strategy for a once-in-a-lifetime cervical cancer screening in a population of 
FSW in Kenya. At higher willingness-to-pay limits, however, our results suggest that, given the 
current information, more data are still required to determine which screening strategy is most 
efficient. 
 
Public Health Significance 
In contrast to the experience of developed countries in the past three decades, no 
significant reduction in ICC incidence has been achieved in low-resource countries due to lack of 
effective screening programs (1, 99). Kenya at this time does not have an established nationwide 
cervical cancer screening program. A once-in-a-lifetime cervical cancer screening in high-risk 
populations in low-resource settings such as our FSW in Kenya using a simple, affordable, and 
accurate test can help begin to reduce ICC incidence and mortality in these regions.  
A recent randomized controlled trial in India reported that compared with no screening 
(control group), a one-time screening with hrHPV DNA testing in participants aged 30-59 years 
was associated with a significant decrease in ICC incidence (hazard ratio: 0.5, 95% CI=0.3-0.7) 
and mortality (hazard ratio: 0.5, 95% CI 0.3-0.8). By contrast, no significant reductions in ICC 
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incidence (hazard ratio: 0.8, 95% CI=0.5-1.1) or mortality (hazard ratio: 0.9, 95% CI=0.6-1.3) 
was found in the conventional cytology testing group, compared with no screening (99).  
A potential limitation to HPV testing in low-resource settings is that HPV testing is 
relatively more expensive (US $20-$30 per test) and typically takes 3.5 to 6 hours to process, 
depending on the test used. HPV testing also requires a sophisticated laboratory infrastructure 
(99). However, data from China showed that a hrHPV DNA test (careHPV, Qiagen, CA), if 
provided via self-collection, has the lowest direct non-medical cost, in terms of savings in 
transportation time and out-of-pocket expenses, compared with other screening strategies (100). 
Findings from our FSW study as well as those of previous studies (Table 2.2) on the 
performance hrHPV self-testing showed that self-collection can be a reliable tool for cervical 
cancer screening.  
Results of our decision analysis showed that hrHPV mRNA testing is potentially more 
costly than conventional cytology (in terms of the number of colposcopies required) due to 
relatively higher sensitivity but lower specificity. However, an evaluation of different cervical 
cancer screening strategies in South Africa found a once-in-a-lifetime screening of women aged 
35 with HC2 hrHPV DNA testing of physician- or self-collected specimens followed by 
treatment on the second visit of screen positive women was cost-effective (according to the 
Commission on Macroeconomics and Health, which defined strategies with a cost-effectiveness 
ratio that is less than the per capita gross domestic product as “very cost-effective”), compared 
with conventional cytology (52). Furthermore, for single lifetime screening, once screening cost 
and impact of screening on lifetime cancer risk and mortality were accounted for, small 
increments in test sensitivity could potentially increase overall screening cost-effectiveness in 
settings with infrequent screening. Changes in test specificity on the other hand have less impact 
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on screening cost-effectiveness, in settings with high disease prevalence and very infrequent 
screening (50).  
 
Strengths  
 Apart from a South African study (47), this study is the only other one to compare hrHPV 
physician- and self-testing for cervical cancer screening in Africa (Table 2.2). Our study is the 
first to use hrHPV mRNA testing in Africa, and also the only so far to compare the risk factors of 
hrHPV mRNA positivity in physician- and in self-collected specimens.   
For the second specific aim of this dissertation, we used data from our study of FSW and 
a population of South African women (with similar ≥HSIL prevalence as in our FSW study) to 
estimate bounds for sensitivity and specificity of hrHPV physician- and self-testing for ≥CIN 2. 
As all three screening programs (conventional cytology and hrHPV physician- and self-testing) 
have already been successfully carried out in our FSW study, we also did not have to make 
assumptions on the availability of screening tests or the feasibility of implementing a screening 
strategy in our population of FSW.  
 
Limitations 
 The small number of ≥HSIL cases (N=15) in our FSW study could have obscured 
potential significant differences in sensitivity of hrHPV mRNA testing for ≥HSIL when using 
physician- compared with self-testing and resulted in the imprecision of our estimates. This 
finding of similar sensitivity was consistent with a previous study that used hrHPV DNA testing 
to detect ≥CIN 2 in high-risk women in Germany (41). In other previous studies, however, the 
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sensitivity of hrHPV DNA for ≥CIN 2 was consistently higher when using physician-testing, 
compare with self-testing (Table 2.2).  
 Our study of FSW also did not have cervical histology data for every woman, since only 
women with cytological ≥HSIL were referred to colposcopy-directed biopsy. Thus, in specific 
aim 1.1 of this dissertation, ≥HSIL was used as screening outcome, instead of histological ≥CIN 
2, potentially limiting the comparability of our results with those of previous studies (Table 2.2).   
 A limitation of the APTIMA HPV Assay used in our study to detect hrHPV mRNA is 
that the assay could not determine if a negative test result interpretation was due to an absence of 
hrHPV or an absence of cells altogether. Although the assay is very sensitive and can detect 
hrHPV mRNA expression levels in as few as one infected cell per reaction, it did not have 
cellular control that would test for the presence or adequacy of a specimen (66). Specimen 
inadequacy is a potential concern especially where it involved self-collected specimens, as we 
could not account for a woman’s adherence to the instructions for self-collection. However, in 
our study, the prevalence of hrHPV among women with valid physician- (30%) and self-
collected specimens (29%) were similar, suggesting that self-collected specimens were 
potentially as reliable as physician-collected specimens for detecting hrHPV.  
 Self-collected specimens are not currently an approved specimen type for the APTIMA 
HPV Assay. The difference in the cellular contents between physician-collected cervical 
specimens and self-collected cervico-vaginal specimens may help explain why some of the self-
collected specimens (N=5) were invalid for hrHPV mRNA testing. Inhibitory substances may 
have been present in these self-collected specimens, perhaps from vaginal substances applied by 
women (L. Guzenski, Hologic Gen-Probe, personal communication). However, it was not 
possible to determine the exact cause of the invalid test results for these specimens.   
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 As with any study that depends on self-reported data, we could not verify the accuracy of 
self-reported information on important risk factors of hrHPV positivity (e.g frequency of condom 
use and number of sexual clients) obtained via interview. Self-reported data would be inaccurate 
if study participants incorrectly recalled or refused to disclose information on risk factors, or if 
participants intentionally responded incorrectly to a question about their sexual history. 
However, interviews were conducted by trained nurses, and participating women were ensured 
of their confidentiality so that they may feel more comfortable in disclosing personal 
information.  
 For our decision analysis, we used a decision model incorporating certain population 
characteristics and test sensitivity and specificity. However, more than one model structure may 
be actually be possible for our research aim (specific aim 2.2), and different models can result in 
variation in the outcomes under evaluation (97).  
Finally, the findings of our study may be generalizable only to similar populations of 
high-risk women with high hrHPV prevalence in low-resource settings, who meet the study 
participation criteria (aged between 18 and 50 years, have an intact uterus and were not in the 
second trimester or later). Also, in our study of FSW, each woman’s physician- and self-
collected specimens were sampled during the same clinic visit. Although this is an advantage of 
our study as it allowed for direct comparison of hrHPV testing results of these two sample types, 
comparisons of our findings with those of other studies where physician- and self-collection 
were conducted at different times (e.g self-collection performed at home, physician-collection at 
the clinic on a different day) should consider the possibility that results may be affected by these 
factors.  
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Future Research Directions 
HrHPV testing of self-collected specimens can potentially help increase screening 
coverage in low-resource areas.  However, more data on hrHPV self-testing for cervical cancer 
screening in low-resource settings are needed, as currently available data are limited (Table 2.2). 
 Although our estimates were imprecise, prevalence of hrHPV in physician- or self-
collected specimens appeared to be higher in women with M. genitalium or T. vaginalis infection 
(Table 4.4). Our finding regarding the potential association between T. vaginalis and hrHPV 
infection was consistent with previous data (86), but the role of M. genitalium or T. vaginalis as 
risk factors of hrHPV infection is still unknown. Longitudinal data are needed to determine if 
infection with M. genitalium or T. vaginalis increases a woman’s risk of hrHPV acquisition or 
persistence.  
 In our study of FSW, physician- and self-collected specimens were sampled in the same 
clinic visit, and participating women were given uniform instructions for self-collection. We 
found that in this setting, hrHPV self-testing was feasible and performed well in detecting 
cervical lesions, compared with physician-testing. Future studies should examine whether our 
findings are reproducible outside a research setting. More data are needed in low-resource 
communities to assess interest and willingness of self-collection, especially among asymptomatic 
healthy women (28). The participation rate of home-based self-collection and effect of different 
types of patient education on self-collection should also be assessed. 
Lastly, data on costs and benefits of hrHPV self-testing for cervical cancer screening in a 
low-resource population with high hrHPV prevalence are very limited (52). Further assessment 
of the test performance as well as total costs and benefits of a cervical cancer screening program 
based on hrHPV self-testing in low-resource settings should be done. Also, screening tests and 
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facilities may not be equally available in all settings. Therefore, future analyses on costs and 
benefits of hrHPV self-testing should consider and provide results for potentially available 
screening strategies, taking into account country-specific circumstances.  
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APPENDIX 
Estimation of bounds of sensitivity and specificity of hrHPV testing for ≥CIN 2 
The following is a estimation of the bounds of sensitivity and specificity of hrHPV 
testing for ≥CIN 2, using data on i) hrHPV testing to detect cytologic ≥HSIL (Table A1) and ii) 
cervical histologic and hrHPV testing results for women with cytologic ≥HSIL (Table A2) 
obtained from our Kenyan FSW study (70), as well as iii) ≥HSIL and histologic ≥CIN 2 (Table 
A3) from a previous study conducted in Cape Town, South Africa (47).  
Table A1. High-risk HPV mRNA testing results by cervical cytology  
 ≥HSIL <HSIL Total 
HrHPV+         
HrHPV-         
Total                 
HrHPV=High-risk human papillomavirus; HSIL=high-grade squamous intraepithelial lesion  
 
Table A2. Cervical histology and high-risk HPV mRNA testing results among women with 
cytologic ≥HSIL 
 ≥CIN 2 <CIN 2 Total 
≥HSIL, hrHPV+        
≥HSIL, hrHPV-        
Total             
CIN=cervical intraepithelial neoplasia; hrHPV=high-risk human papillomavirus HSIL=high-grade 
squamous intraepithelial lesion 
 
Table A3. Cervical cytology results by histology  
 ≥CIN 2 <CIN 2 Total 
≥HSIL         
<HSIL         
Total                 
HSIL=high-grade squamous intraepithelial lesion; CIN=cervical intraepithelial neoplasia 
 
Maximum likelihood estimation was used to draw inference about the sensitivity and 
specificity of hrHPV testing for ≥CIN2. We let   ,       denote the probabilities 
corresponding to the eight possible test outcomes (Table A4) should a woman be given all three 
screening tests. We assume that in our Kenyan FSW study (70), the data on histologic ≥CIN 2 
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were missing at random (MAR) (101), as cervical histology was available for women with 
cytologic ≥HSIL but not for women with <HSIL. Under the MAR assumption, the log likelihood 
for the observable data in Tables A1, A2 and A3 is: 
                                                               
          +                                                     
As can be seen from the log-likelihood, parameters   ,        and     are identifiable from the 
observable data, while parameters    ,        and     are only partially identifiable (although the 
terms        ,        ,         and [       are each identifiable). As a result, the 
maximum likelihood estimators (MLEs) of the sensitivity and specificity are not unique.  
Table A4. Possible outcomes of screening by high-risk HPV testing, cervical cytology and 
cervical histology in female sex workers in Kenya 
 Testing result  
Parameter  HrHPV ≥CIN 2 ≥HSIL 
   negative negative negative 
   negative negative positive 
   negative positive negative 
   negative positive positive 
   positive negative negative 
   positive negative positive 
   positive positive negative 
   positive positive positive 
HrHPV=High-risk human papillomavirus; CIN=cervical intraepithelial neoplasia; HSIL=high-grade 
squamous intraepithelial neoplasia 
 
Let  ̂   ̂   ̂  denote the resulting estimates of   ,      . The estimated sensitivity 
and specificity of hrHPV testing for ≥CIN 2 are: 
              
 ̂   ̂ 
 ̂   ̂   ̂   ̂ 
 
            
 ̂   ̂ 
 ̂   ̂   ̂   ̂ 
 
To obtain the lower sensitivity bound (i.e the smallest MLEs), the log-likelihood was first 
maximized under    constrained to a range of values (e.g.        01, 0.02,…0.98, 0.99, 1.00), 
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since     and the denominator for calculating sensitivity (             are identifiable. 
The smallest value of    where the log-likelihood was the same as when    was not constrained 
was used to determine the minimum value for sensitivity. Similarly, the largest value of    
where the log-likelihood equals that under    unconstrained was used to determine the 
maximum value for sensitivity (i.e the largest MLEs). Analogous methods were used to obtain 
the lower and upper specificity bounds, with the log-likelihood maximized under    constrained 
to a range of values.  
Standard errors for the upper and lower bound sensitivity estimates were estimated using 
the delta method (102). To take into account the uncertainty due to sampling variability, we 
constructed the approximate 95% CI for the true sensitivity by (103): 
           ̂     ⁄   ( ̂ )   ̂     ⁄   ( ̂ )  
where  ̂  is the lower bound sensitivity estimate,   ̂  the upper bound sensitivity estimate, 
and   ( ̂ ) and   ( ̂ ) are the corresponding estimated standard error.  The critical value    ⁄  
was calculated as the solution to the following equation (103): 
   [     ⁄    {    ⁄  
  ̂   ̂ 
  ( ̂ )
}   {   ⁄  
  ̂   ̂ 
  ( ̂ )
}        ⁄   ]      
where     is the cumulative distribution function of a normal standard variate. Analogous 
methods were used to estimate the standard errors and 95% CI of the true specificity. 
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